ISHIB2009 - International Society on Hypertension in Blacks

24th Annual <strong>International</strong> Interdisciplinary Conference 

on Hypertension and Related Cardiovascular Risk Factors in Ethnic Populations 

ProgramSyllabus 

 

 

 

 

 

 

 

Jointly sponsored by ISHIB 

and the American <strong>Society</strong> of Hypertension, Inc. (ASH) 

July 10 - 12, 2009

ABOUT ISHIB 

The <strong>International</strong> <strong>Society</strong> on Hypertension in Blacks, Inc. (ISHIB) is a unique, nonprofit, professional medical membership organization 

devoted to improving the health and life expectancy of ethnic minority populations. ISHIB was founded in Atlanta, Georgia in 1986 

to respond to the problem of high blood pressure among ethnic minority populations. The organization’s scope includes diabetes, 

stroke, lipid disorders, renal disease, and other related cardiovascular risk factors. The objectives of the <strong>Society</strong> are: 

• to promote public awareness of the harmful effects of hypertension and related risk factors, especially among ethnic 

populations; 

• to develop health-related programs to improve the quality of life in ethnic populations worldwide; 

• to educate the public on ways to prevent the complications of hypertension and other related risk factors; 

• to stimulate research and clinical investigation; and 

• to disseminate scientific findings to aid in the understanding of differences in hypertension and related risk factors. 

<strong>International</strong> 

Interdisciplinary Conference 

The <strong>Society</strong> sponsors an annual international conference. 

Begun in 1985, the conference attracts recognized lecturers 

and an audience of international health professionals who 

want to learn the latest in clinical research and educational 

methodology. 

E T H N I C I T Y & DISEASE 

The <strong>Society</strong>’s peer-reviewed, refereed medical journal is a 

highly respected source of information on disease patterns 

in ethnic populations throughout the world. Guided by a 

distinguished international editorial board, this publication 

offers original reports, reviews, and commentaries by 

physicians and scientists engaged in medical research. The 

journal is indexed in Index Medicus, MEDLINE, BIOSIS, and 

Cambridge Scientific. 

Clinical Guidelines 

Through collaboration with United States medical experts, 

ISHIB developed the first-ever guidelines for treating high 

blood pressure in African Americans. Published in Archives 

of Internal Medicine, the recommendations are endorsed by 

leading health organizations including: the American Heart 

Association, the Association of Black Cardiologists, the 

Consortium for Southeastern Hypertension Control, and the 

National Medical Association. 

Research 

The <strong>Society</strong>’s research unit conducts clinical trials related 

to hypertension prevention, treatment, and management as 

well as data gathering and analysis of current disease trends. 

ISHIB is regarded as a resource for protocol development, 

study management, and patient recruitment. 

IMPACT Campaign 

The ISHIB IMPACT Campaign is a comprehensive, evidencebased 

strategy for improving the health of minority patients 

with hypertension and related cardiovascular disease. This 

three-stage program promises to: 

• Advance the scientific knowledge base through an understanding 

of current science and clinical research; 

• Improve the guidelines for managing hypertension in African 

Americans and other at-risk populations; 

• Promote this knowledge and the new guidelines by using 

models of social change to achieve sustained, meaningful 

modification in the health behaviors of patients and 

their caregivers. 

The campaign will target healthcare professionals, patients, 

family members, and caregivers. It will provide strategies for 

healthy lifestyles, self-management tips, treatment and control 

options, and prevention techniques. 

Accredited Professional 

Educational Programs 

In cooperation with leading healthcare institutions, ISHIB 

develops and implements accredited educational programs 

for physicians, nurses, pharmacists, and other allied health 

professionals who care for ethnic patients with hypertension 

and other co-morbid cardiovascular diseases. 

Patient and Community 

Education 

To promote public awareness about the dangers of high 

blood pressure and co-morbid cardiovascular diseases, the 

<strong>Society</strong> conducts patient and community education programs 

throughout the year. Programs, such as the Worship-Site 

Health Education Program, are designed to meet the needs 

of the community to reduce risk factors related to hypertension 

and to help adults maintain healthy lifestyles. ISHIB initiatives 

have included health promotion, disease prevention and 

treatment, as well as community-based research activities.

Dear Conference Attendees: 

We are delighted that you are joining the 24th Annual <strong>International</strong> Interdisciplinary Conference 

on Hypertension and Related Cardiovascular Risk Factors in Ethnic Populations. We will all benefit 

from your participation at this year’s meeting, which has been designed and delivered by a multidisciplinary 

team of your colleagues. We hope the indepth scientific sessions will inform, inspire and 

motivate you to continue your work in minority health. 

For the last year, the <strong>ISHIB2009</strong> scientific committee has assessed the scientific literature, reviewed 

current gaps in the knowledge base, and examined topic possibilities to bring you the most pertinent 

data and information. Throughout the next three days, you will notice a wide variety of topics 

addressing issues ranging from reaching Healthy People 2010 goals to improving public policy on 

health insurance to understanding risk reduction measures for African Americans with metabolic 

syndrome and to learning how cardiovascular risk factors are linked to chronic kidney disease. 

To make the most of your participation in <strong>ISHIB2009</strong>, we invite you to take in the three plenary 

sessions, seven workshops, three symposia and the half-day Hypertension Academy. Interact with 

session presenters and do not leave a session until your questions are answered or your statements 

are made. Attend the abstract poster presentations to learn the latest research on this year’s theme: 

Eliminating disparities in hypertension, metabolic syndrome, kidney failure and cardiovascular disease: 

basic science, clinical practice and community initiatives. 

When the scientific program gives you a break, the city of Chicago awaits you. If your family has 

accompanied you, be assured that their days will be filled with new explorations and memorable sites. 

Finally, while the science from this year’s meeting will expand research messages across many 

specialties, we salute you for your subsequent work utilizing the meetings’ messages in healthcare 

settings. Let this year’s conference information carry you into the next year with new ideas and a 

continued quest for solutions to end health disparities among ethnic minority populations. 

Regards, 

Keith C. Ferdinand, MD 

Conference Co-Chair 

Keith C. Norris, MD 

Conference Co-Chair

PartOne 

Conference Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 

Program-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 

Meeting Facility Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 

Conference Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 

The ISHIB Organization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 

PartTwo 

Conference Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 

Friday, July 10 

Hypertension Academy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 

Opening Ceremony Luncheon/Neil Shulman Lecture . . . . . . . . . . . . . . . . . . . . . . 15 

Exhibition and Abstract Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 

Plenary Session I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 

Workshop A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 

Workshop B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 

President’s Recognition and Awards Ceremony Reception . . . . . . . . . . . . . . . . . . . 20 

Dinner Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 

Saturday, July 11 

Breakfast Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 

Plenary Session II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 

Exhibition and Abstract Poster Sessions and Industry Expert Theater . . . . . . . . . . . . 24 

Lunch Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 

Annual Members’ Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 

Workshop C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 

Workshop D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 

Dinner Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 

Sunday, July 12 

Breakfast Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 

Plenary Session III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 

Exhibition and Abstract Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 

Workshop E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 

Workshop F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 

Lifestyle Modification Workshop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 

PartThree 

Faculty Contact Information and Biographies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 

PartFour 

Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 

PartFive 

Exhibitors/Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 

TableOfContents 

Chicago photos courtesy of Chicago 

Convention and Tourism Bureau


PartOne 

ConferenceInfo 

theISHIBorganization

FriJuly10 

4 

4 

4 

7:30 AM to 11:30 AM 

Hypertension Academy 

Basic Principles of Effective Hypertension 

Therapeutics - J FLACK 

Hypertension Case Management 

- A BROWN 


- J WRIGHT 

Effective BP Lowering and Target 

Organ Protection in Patients with 

Compromised Kidney Function 

- E CROOK 

New Antihypertensive Agents 

- G BAKRIS 

Optimal Utilization Diuretics in 

Antihypertensive Regimens - D SICA 

11:45 AM to 1:00 PM 

Opening Ceremony/ 

Neil Shulman Lecture 

Welcome - K NORRIS 

Conference Overview and Objectives 

- K FERDINAND 

Introduction and Acknowledgement 

of ISHIB Founders - K JAMERSON 

Welcome from the City of Chicago 

- T MASON 

Public Health Policy: The Impact of 

City Health Departments in Shaping 

Policy - T MASON 

The Emerging Plans for Healthcare 

Reform: An Update on the Obama 

Administration’s Vision for Health 

- ADMINISTRATION REPRESENTATIVE 

Conclusion - K NORRIS 

1:00 PM 

to 2:30 PM 

Exhibition 

and 

Abstract 

Poster 

Session 

2:30 PM to 4:00 PM 

Plenary Session I 

Healthy People 2010: 

Are We There Yet? 

Blue Ribbon Presentation 

- N MERCHANT 

Healthy People 2010: The Update 

- P SLADE-SAWYER 

Changing the Cardiovascular Profile 

for African American Patients 

and Other High Risk Minorities 

- E SAUNDERS 

SatJuly11 

7:30 AM to 8:30 AM 

Breakfast Session 

How to Become More 

Involved in ISHIB 

Come have breakfast with three 

ISHIB Board of Trustee members 

and learn more about ISHIB and 

the activities the organization is 

involved in. Learn how you can 

become a member or more active 

in some of the projects and initiatives 

of the organization. 

- WD HALL 

- S NESBITT 

- E SAUNDERS 

8:30 AM to 10:00 AM 

Plenary Session II 

Diabetes: New Age - Is it 

Beneficial or Harmful? 


- D KEREIAKES 

Glycemic Targets and Cardiovascular 

Outcomes: From UKPS, 

VADT, ADVANCE to ACCORD 

- D KENDALL 

Management of Hypertension in 

African Americans With Diabetes 

- J REED 

Management of Lipids in African 

Americans - A SUMNER 

10:00 AM 

to 11:30 AM 


and 

Abstract 

Poster 


11:30 AM to 1:30 PM 

Lunch Symposium 

Glycemic Targets in Patients 

with Type 2 Diabetes: A New 

Era? 

Hypoglycemic Targets: Interpreting 

Latest Trial Evidence - D KENDALL 

Managing CV Risk in African 

Americans With Type 2 Diabetes 

and Hypertension - K FERDINAND 

Panel Discussion. Managing Risk in 

an African American Patient With 

Hypertension and Diabetes - K OSEI 

SunJuly12 

7:30 AM to 8:30 AM 


Ask the Experts, A Discussion 

of Practical Case Studies 

Come join our expert panel as 

they present practical case studies. 

Cases will be discussed from an 

internal medicine, cardiology, and 

nephrology point of view by our 

expert panel representing their 

respective specialties. 

- K FERDINAND 

- D KOUNTZ 

- K NORRIS 

8:30 AM to 10:00 AM 

Plenary Session III 

Chronic Kidney Disease: 

Early Diagnosis and Halting 

the Progression 


- R WATSON 

Chronic Kidney Disease Staging: 

The Pros and Cons - S NICHOLAS 

Management of Hypertension in 

the CKD Patient - J LEA 

10:00 AM 

to 11:00 AM 


and 

Abstract 

Poster 


11:00 AM to Noon 

Workshop E 

Treatment of Anemia and 

Metabolic Derrangements 

and Chronic Kidney Disease: 

What is Appropriate and 

What is Not 

Treatment of Anemia in CKD: 

Impact on CVD - RM CULPEPPER 

Impact of Treating Elevated Lipids, 

Glucose, and Inflammatory Markers 

on CKD - JK TUCKER 


ProgramAtAGlance



FriJuly10 

4:00 PM 

to 4:30 PM 


and 

Abstract 

Poster 


4:30 PM to 5:30 PM 

Workshop A 

Target Organ Damage and 

the Importance of Staging: 

Cardiovascular Disease 

An Overview of Left Ventricular 

Hypertrophy - CJ RODRIGUEZ 

High Risk Patients: Kidney Disease, 

Dialysis and Hypertension - M 

KLEINPETER 

4:30 PM to 5:30 PM 

Workshop B 

Can We Afford to Insure 

Everyone? 

Health and Economic Toll of 

Under- and Uninsured Groups in 

South Carolina and Beyond: Can 

We Afford Not to Insure Everyone? 

- D LACKLAND 

Healthcare Access - S THORNE 

5:30 PM to 6:30 PM 

President’s Recognition and 

Awards Ceremony Reception 

Welcome - K JAMERSON 

Presentation to Award Recipients 

- S NESBITT 

Conclusion - K JAMERSON 

6:30 PM to 8:30 PM 

Dinner Symposium 

Blood Pressure Management 

and Risk Reduction in African 

American Patients with Metabolic 

Syndrome: What are the Best 

Approaches? 

Components of the Metabolic Syndrome 

In African American Patients - J SOWERS 

Inflammatory Markers In Cardiovascular 

Disease - S NESBITT 

Combination Therapy in African Americans 

With Hypertension And Metabolic 

Syndrome: What Are The Best Choices? 

- K FERDINAND 

Panel Discussion. Cases in Point: Addressing 

The Challenges in African 

American Patients With Hypertension And 

Metabolic Syndrome - K FERDINAND 

SatJuly11 

5 

5 

5 

1:30 PM 

to 2:30 PM 

Annual 

Members’ 

Meeting 

2:30 PM 

to 3:30 PM 


and 

Abstract 

Poster 


3:30 PM to 4:30 PM 

Workshop C 

Understanding Genomics: 

Basics and Beyond 

An Update on Genomic Profiling: 

New Technologies and Methodologies 

- J CARPTEN 

Ancestry, Genetic Association, and 

Hypertension - J WILSON 

3:30 PM to 4:30 PM 

Workshop D 

Heart Failure 

Comparison of Heart Failure in the 

Minority Populations - I PIÑA 

Systolic and Diastolic Heart Failure 

- A ONWUANYI 

4:30 PM 

to 6:30 PM 


and 

Abstract 

Poster 


Industry 

Expert 

Theater 

6:30 PM to 8:30 PM 


Oxidative Stress, Endothelial 

Function and Beta Blockade in 

Hypertensive Disease: A Fresh 

Look at African American Patients 

Oxidative Stress, Endothelial Function, 

and Beta Blockade: Newest Findings 

- G GIBBONS 

Hypertensive Disease Management in 

African Americans: Interpreting The Role 

of Beta Blockade - E OFILI 

Faculty Case Discussion. An Elderly African 

American Patient With Hypertension 

and Angina - K JAMERSON 

SunJuly12 


Workshop F 

Vitamin D and Chronic 

Diseases 

Vitamin D Overview- What Clinicians 

Need to Know - D WALLIS 

Vitamin D and Chronic Kidney 

Disease - K NORRIS 

Noon 

to 12:30 PM 


and 

Abstract 

Poster 


12:30 PM to 2:00 PM 

Lifestyle Modification 

Workshop 

Introduction: Improving Adherence 

and Self-Management within the 

Chronic Care Model - R PETERS 

Office System Factors Affecting 

Adherence: Decision-Support 

Mechanisms - T LONG 

Provider Factors Affecting Adherence: 

Cultural Competency and 

Sensitivity - D BARKSDALE 

Patient Factors Affecting Adherence: 

Empowering Patients for 

Self-Management - R BENKERT 


ProgramAtAGlance

6 

6 

6 


Meeting 

Facility 

Floor Plan 

Renaissance 

Chicago 

Hotel



Registration Schedule 

Thursday, July 9 




Noon – 5:00 PM 

7:00 AM – 5:00 PM 

8:00 AM – 4:30 PM 

8:00 AM – 3:00 PM 

Onsite Payment 

Credit cards (American Express, Visa, MasterCard or Discover) 

or certified bank drafts in US funds will be accepted 

for onsite registration. 

Registration Fee Includes 

• Conference bag and one name badge 

• Program syllabus and other meeting 

documentation 

• Admission to all scientific programs, satellite symposia 

and exhibit hall functions 

• Admission to the President’s Recognition Reception 

• Eligibility to receive education credits 

Guest Registration 

Onsite guests must register on the conference attendee’s 

form for an additional fee of $250. Guests are not allowed 

in the scientific halls during scientific events. Guests 

are welcome at the following <strong>Society</strong>-sponsored non-scientific 

conference programs: 

• Opening Ceremony 

• President’s Recognition Reception 

• Abstract and Exhibit reception 

Guests will NOT receive CME, CEU, or CE credits unless 

they have paid the conference registration fee. 

Badges 

Identification badges are required for admission to all 

session and events. Badges for registered conference 

attendees and guests may be obtained at the registration 

desk. Replacement badges may be obtained at an additional 

cost of $50. 

Accreditation 

This activity has been planned and implemented in accordance 

with the Essential Areas and Policies of the 

Accreditation Council for Continuing Medical Education 

(ACCME) through the joint sponsorship of the American 

<strong>Society</strong> of Hypertension, Inc. and ISHIB. The American 

<strong>Society</strong> of Hypertension, Inc. is accredited by the ACCME 

to provide continuing medical education for physicians. 

Designation 

The American <strong>Society</strong> of Hypertension, Inc. designates this 

educational activity for a maximum of 22 hours AMA PRA 

Category 1 credits. Each physician should claim credit 

commensurate with the extent of their participation in the 

activity. 

CE credits for nurses, dietitians, and other healthcare 

professionals requiring continuing education credits will 

be provided by ISHIB. ISHIB has been reviewed and approved 

as an authorized provider by the <strong>International</strong> Association 

for Continuing Education and Training (IACET) 

and uses the criteria and guidelines designated by that 

organization as the basis for granting continuing education 

units (CEUs). Participants who successfully complete 

this activity can receive up to 2.2 CEUs. 

CE credits for pharmacists will be provided by the National 

Pharmaceutical Association. 

Disclosure Policy 

The American <strong>Society</strong> of Hypertension, Inc. strives to 

ensure balance, independence, objectivity, and scientific 

rigor in all of its educational activities. All presenters in 

such activities are expected to disclose to the program audience 

any real or apparent conflict(s) of interest that may 

have a direct bearing on the subject matter of the session 

in which they are participating. This pertains to relationships, 

in place at the time of the activity or in the twelve 

(12) months preceding the activity, with pharmaceutical 

companies, biomedical device manufacturers, or other 

corporations whose products or services are related to the 

subject matter of the presentation topic. Speakers are also 

expected to openly disclose any off-label, experimental, or 

investigational use of drugs or devices in their presentations. 

Speaker Ready Room 

Printers Row - 3rd Floor 

A speaker ready room is located in the Printers Row room 

on the 3rd floor and is provided for all speakers. Please 

visit this room to prepare for your audiovisual presentations. 

Volunteer staff will be available to provide assistance. 

No Smoking 

It is a policy of ISHIB that the use of tobacco products is 

strictly prohibited in all areas of the hotel meeting rooms 

hosting ISHIB events. Thank you for not smoking. 

7 

7 

7 

ConferenceInfo

Conference Attire 

<strong>ISHIB2009</strong> meeting attire is business casual. Participants 

might plan on business dress for evening dinner symposia. 

Session Recording 

Conference attendees are asked to refrain from video or 

audio taping during sessions. 

8 

8 

8 

Copyright 

The copyright to all papers presented at <strong>ISHIB2009</strong> is 

vested with ISHIB. If an author or his/her organization 

wishes to reprint the paper, applications should be made 

in writing beforehand to ISHIB — Program Manager. If 

written permission is given, the distribution of the paper 

shall not take place before the start of the conference. 

Publication of Proceedings 

Authors have been asked to submit ready-to-be published 

papers of their presentations at <strong>ISHIB2009</strong>. A supplement 

to Ethnicity & Disease will feature these papers and 

proceedings of the conference. Please submit your paper 

at the registration counter. 

Exhibit Hall Schedule 

Grand Ballroom IV, V, VI 




1:00 PM – 2:30 PM 

4:00 PM – 4:30 PM 

5:30 PM – 6:30 PM 

10:00 AM –11:30 AM 

2:30 PM – 3:30 PM 

4:30 PM – 6:30 PM 

10:00 AM – 11:00 AM 


ConferenceInfo



<strong>ISHIB2009</strong> 

Joint Sponsors 

<strong>International</strong> <strong>Society</strong> 

on Hypertension 

in Blacks, Inc. 

American <strong>Society</strong> 

of Hypertension, Inc. 

2009 ISHIB 

Supporters 

PLATINUM 

Daiichi Sankyo, Inc. 

Forest Laboratories, Inc. 

Novartis Pharmaceuticals 

Takeda Pharmaceuticals 

North America, Inc. 

DIAMOND 

Merck & Company 

2009 Corporate 

Partners 

Roundtable 


Forest Laboratories, Inc. 

GlaxoSmithKline 

Merck & Company 

9 

9 

9 

GOLD 


COMMUNITY SPONSOR 

Softsheen Carson 


Takeda Pharmaceuticals 

North America, Inc. 

ISHIB Councils 

Diabetes/Metabolic 

Syndrome 

Kwame Osei, MD - chair 

Brent M. Egan, MD - co-chair 

Emelia P. Amoako, PhD, APRN-BC 

Eric W. Ayers, MD 

Angela Brown, MD 

Ronald A Codario, MD 

Evelyn F. Crayton, EdD, RD, LD 

Johnnie L. Early, II, PhD, RPh 

Bonita E. Falkner, MD 

W. Dallas Hall, MD 

Denice M. Logan, DO 

James W. Reed, MD 

Anne E. Sumner, MD 

Idella Whitfield-Stith, RN, BSN 

Heart Failure 

Domenic A. Sica, MD - chair 

C. Venkata Ram, MD - co-chair 

Albert A. Carr, MD 

Charles L. Curry, MD 

Mahfouz El Shahawy, MD, MS 

Josiah K. Halm, MD 

L. Julian Haywood, MD 

Temple O. Robinson, MD 

Elijah Saunders, MD 

Fadia T. Shaya, PhD, MPH 

Jackson T. Wright, Jr., MD, PhD 

theISHIBorganization 

Kidney Disease 

Janice P. Lea, MD - chair 

Randall W. Maxey, MD, PhD - co-chair 

Lawrence Y.C. Agodoa, MD 

Wendy W. Brown, MD, MPH 

DeAnna E. Cheek, MD 

Errol D. Crook, MD 

John M. Flack, MD, MPH 

Rosalind M. Peters, PhD, RN 

Matthew R. Weir, MD 

Lipids 

Karol E. Watson, MD, PhD - chair 

Keith C. Ferdinand, MD - co-chair 

Samar A. Nasser, PA-C, MS 

Shawna D. Nesbitt, MD, MS 

Raquel C. Perkins, PharmD, RPh 

L. Michael Prisant, MD 

Randall Tackett, PhD 

Obesity 

David S. Kountz, MD - chair 

Carlene M. Grim, RN, MSN, SpDN - co-chair 

Sharon K. Davis, PhD 

Clarence E. Grim, MD 

Robert H. Schneider, MD 

Mary S. Webb, PhD, RN 

Stroke 

Jacqueline M. Washington, MD - chair 

Wallace R. Johnson, Jr., MD - co-chair 

Edward S. Cooper, MD 

Edgar J. Kenton, III, MD 

Daniel T. Lackland, DrPH 

Corliss A. McKeever, MSW 

Salina Waddy, MD

10 

10 

10 

 

<strong>ISHIB2009</strong> Scientific 

Planning Committee 

Keith C. Ferdinand, MD - Co-chair 

Keith C. Norris, MD - Co-chair 

Errol D. Crook, MD 

Brent M. Egan, MD 


Rick A. Kittles, PhD 

Daniel T. Lackland, DrPh 

Janice P. Lea, MD 

Anekwe E. Onwuanyi, MD 

Kwame Osei, MD 

Randall S. Otelio, MD 

Rosalind M. Peters, PhD, RN 

<strong>ISHIB2009</strong> Abstract 

Review Committee 

Clarence E. Grim, MD - Chair 

Carolyn M. Brown, PhD 

Bernell R. Coleman, PhD 

German T. Hernandez, MD 

Michel Joffres, MD, PhD 

Daniel T. Lackland, DrPH 

Aryel Nicoleau, MD 

Ike S. Okosun, MS, MPH, PhD 

George P. Patrinos, PhD 

ISHIB Board of Trustees 

Kenneth A. Jamerson, MD - President 

Shawna D. Nesbitt, MD, MS - Vice President 

David S. Kountz, MD - Secretary/Treasurer 

Charles L. Curry, MD - Immediate Past President 

George L. Bakris, MD 

Brent M. Egan, MD 


James R. Gavin III, MD, PhD 

Clarence E. Grim, MD 

W. Dallas Hall, MD - Lifetime Trustee 

Sandra A. Harris-Hooker, PhD 

Janice P. Lea, MD 

Keith C. Norris, MD 

C. Venkata S. Ram, MD 

James W. Reed, MD - Lifetime Trustee 

Elijah Saunders, MD - Lifetime Trustee 

Jackson T. Wright, Jr., MD, PhD 

ISHIB Staff 

Jack Hannings - Executive Director 

Terry E. Jackson - Senior Program Director 

<strong>ISHIB2009</strong> Volunteers 

Kathy Allen 

Brook A. Bloxson 

Sherald Glover 

Felicia Gonzaque 

Ashley Hannings 

Andrea Jones 

Kim Samuels 

Emma Taylor 

Elizabeth (Liz) Williamson 

Marilyn Wallace Wilson 

theISHIBorganization


PartTwo 

ConferenceProgram

<strong>ISHIB2009</strong> Program Objectives 

At the completion of <strong>ISHIB2009</strong> programming, the participants should be able to: 

• Diagnose and effectively treat hypertension in the presence of co-existing cardiovascular, 

renal and metabolic risk factors. 

• Describe the emerging plans that President Barack Obama’s new administration 

has for healthcare reform and how it can eliminate disparities by integrating basic 

science, clinical practice and community initiatives. 

12 

12 

12 

• Recognize the association of high blood pressure, metabolic syndrome, and kidney 

disease as key risk factors for cardiovascular events and premature mortality. 

• Describe our progress in achieving Healthy People 2010 goals for hypertension, 

metabolic diseases and diabetes, kidney and cardiovascular diseases. 

• Describe the staging for target organ damage in patients with cardio-metabolic 

diseases. 

• Recognize the strengths and limitations of the Obama administration’s plan for 

health care reform and universal health insurance coverage. 

• Understand the importance of lifestyle modification and self/community empowerment 

for improving cardio-metabolic outcomes. 

Community Outreach 

Preceding <strong>ISHIB2009</strong>, ISHIB sponsored a community health screening event in 

conjunction with the National Kidney Foundation and Access Community Health 

Network at the South Side YMCA. ISHIB remains committed to its roots by ensuring 

we incorporate a community component to all major activities of the organization. We 

wish to thank those companies who helped to sponsor this event. 



Takeda Pharmaceuticals North America, Inc. 

Softsheen Carson 

Breakfast 

7:00 AM to 8:30 AM 

Outside Grand 

Ballroom I,II,III 

FriJuly10SatJuly11SunJuly12



Hypertension Academy 

Session Objectives 

Upon completion of this activity, participants should be able to: 

• Gain familiarity with solutions to commonly encountered clinical problems that 

undermine blood pressure control and target-organ protection when treating 

hypertensive African Americans 

• Explain specific, in-depth knowledge of optimal diuretic use in hypertension 

treatment 

• Apply knowledge of hypertension evaluation, risk stratification, and therapeutics 

to case scenarios 

7:30 AM to 11:30 AM 

Grand Ballroom I, II, III 

CME: 4.0 CEU: .4 

Chair 

JOHN M. FLACK, MD, MPH 

Faculty 

ANGELA L. BROWN, MD 

JACKSON T. 

WRIGHT, JR., MD, PHD 

ERROL D. CROOK, MD 

GEORGE L. BAKRIS, MD 

DOMENIC A. SICA, MD 

13 

13 

13 

Overview 


Basic Principles of Effective Hypertension Therapeutics 



• Explain the basic approaches to hypertension diagnosis, risk stratification, and 

selection of antihypertensive drug therapies 

• Utilize better understand approaches to patients with resistant hypertension and 

limited financial resources 




• Utilize current treatment guidelines to manage hypertension 

• Direct hypertension therapy based on patient risk and evidence of target organ 

damage 



JACKSON T. WRIGHT, JR., MD, PHD 


• Make decisions that will markedly improve the likelihood of BP control in a 

patient with multiple co-morbidities and resistant hypertension 

• Describe the relevant issues concerning the timing of dose up-titration and pressure-related 

side effects that can influence BP control and patient adherence 

JACKSON T. 

WRIGHT, JR., MD, PHD 


Effective BP Lowering and Target Organ Protection in Patients with 

Compromised Kidney Function 



• Gain a comprehensive understanding of the diagnostic and therapeutic approach 

to lowering blood pressure and preservation of kidney function in hypertensives 

with compromised kidney function 

• Report how to anticipate and avoid, or at least react appropriately to, common 

problems encountered when treating hypertension in patients with compromised 

kidney function 


14 

14 

14 

Break 

New Antihypertensive Agents 



• Identify the newer antihypertensive agents and to gain an understanding of their 

utility in the contemporary antihypertensive therapeutic armamentarium 


Optimal Utilization Diuretics in Antihypertensive Regimens 



• Gain a keen understanding of the different classes of diuretics and approaches 

for their use, alone as well as with a second diuretic, in complex antihypertensive 

drug regimens 

• Describe the physiological basis for common diuretic-linked problems such as 

hypokalemia, hypomagnesemia and explain strategies for their prevention and 

treatment 


Conclusion 





Opening Ceremony/Luncheon 

Neil Shulman Lecture 

Welcome 

KEITH C. NORRIS, MD 

Conference Overview and Objectives 

KEITH C. FERDINAND, MD 

11:45 AM to 1:00 PM 


CME: 1.0 CEU: .1 

Conference Co-Chairs 



ISHIB President 

KENNETH A. JAMERSON, MD 

Guest Speaker 

TERRY MASON, MD 

15 

15 

15 

Introduction and Acknowledgement of ISHIB Founders 


Welcome from the City of Chicago 


Chicago Health Commissioner 


Public Health Policy: The Impact of City Health Departments 

in Shaping Policy 



The Emerging Plans for Healthcare Reform: An Update 

on the Obama Administration’s Vision for Health 

ADMINISTRATION REPRESENTATIVE - TBA 




FriJuly10SatJuly11SunJuly12 

TERRY MASON, MD


and Abstract Poster Sessions 

1:00 PM – 2:30 PM 

Merit Posters 

1:00 PM to 2:30 PM 

4:00 PM to 4:30 PM 


16 

16 

16 

010 - Delayed Diagnosis/Management of Primary 

Aldosteronism — Help from The Web: A Support 

Group for Patients Struggling with This Common 

Cause of Difficult-to-Control High Blood Pressure 

CLARENCE GRIM 

009 - Building Partnerships in Urban Communities 

through Focus Groups 

DEBORAH JONES 

019 - The Association between Health Literacy 

and Glycemic Control among Mexican American 

Diabetics with Chronic Kidney Disease: A Preliminary 

Report from the Paso Del Norte Kidney Disease 

Study (PNKDS) 

GERMAN HERNANDEZ 

4:00 PM – 4:30 PM 

Merit Posters 

008 - Health Literacy and Language Preference in 

Hispanics with Chronic Kidney Disease 

CLAUDIA LORA 




Plenary Session I 

Healthy People 2010: Are We There Yet? 



• Explain the current status and progress on achieving Healthy People 2010 goals 

and objectives 

• Explain the current status and progress on developing Healthy People 2020 

goals and objectives 

• Discuss opportunities for attendees to become involved in the Healthy People 

2020 development process 

2:30 PM to 4:00 PM 


CME: 1.5 CEU: .15 

Chair 

ELIJAH SAUNDERS, MD 

Guest Speaker 

REAR ADMIRAL PENELOPE 

SLADE-SAWYER, PT, MSW 

17 

17 

17 

Introduction 



020 - Nebivolol in High-risk, Obese African Americans With Stage 1 

Hypertension: Effects on Blood Pressure, Nitric Oxide Bioavailability, and 

Vascular Function 

NADYA MERCHANT 


Healthy People 2010: The Update 

REAR ADMIRAL PENELOPE SLADE-SAWYER, PT, MSW 


• Explain the current status and progress on achieving Healthy People 2010 goals 

and objectives 

• Explain the current status and progress on developing Healthy People 2020 

goals and objectives 

• Discuss opportunities for attendees to become involved in the Healthy People 

2020 development process 

REAR ADMIRAL PENELOPE 

SLADE-SAWYER, PT, MSW 

Changing the Cardiovascular Profile for African American Patients 

and Other High Risk Minorities 





18 

18 

18 

 

Workshop A 

Target Organ Damage and the Importance 

of Staging: Cardiovascular Disease 



• Understand the evaluation, determinants and consequences of left ventricular 

hypertrophy 

• Identify patients at high risk of developing kidney disease 

• Explain the rationale for the types of recommended treatment and target goal 

blood pressure 

• Identify whether high blood pressure discriminates among target organs 

• Discuss possible physio-pathological mechanisms of how and why high blood 

pressure impacts specific target organs 

4:30 PM to 5:30 PM 


CME: 1.0 CEU: .1 

Chair 

OTELIO S. RANDALL, MD 

Faculty 

CARLOS JOSE 

RODRIGUEZ, MD, MPH 

MYRA A. KLEINPETER, MD 



An Overview of Left Ventricular Hypertrophy 

CARLOS JOSE RODRIGUEZ, MD, MPH 

• Describe the methodology for measuring left ventricular hypertrophy 

• Discuss the adverse prognosis of left ventricular hypertrophy and its role in 

cardiovascular risk assessment 

• Understand determinants of left ventricular hypertrophy including race 

• Identify ways to modify left ventricular hypertrophy 


High-Risk Patients: Kidney Disease, Dialysis and Hypertension 



• Identify high-risk patients for developing chronic kidney disease 

• Initiate appropriate treatment strategies in the management of cardiovascular 

risk factors in patients with chronic kidney disease 

• Integrate a multidisciplinary team approach to manage patients with chronic 

kidney disease 

CARLOS JOSE 

RODRIGUEZ, MD, MPH 







Workshop B 

Can We Afford to Insure Everyone? 



• Recognize factors, including insurance status, that facilitate and impede access 

to effective health care 

• Describe the impact of insurance status on productivity and cost-avoidance opportunities 

• Enumerate the relative per capita healthcare costs in countries with universal 

and restricted access 

4:30 PM to 5:30 PM 

Cuisines 

CME: 1.0 CEU: .1 

Chair 

BRENT M. EGAN, MD 

Faculty 

DANIEL T. LACKLAND, DRPH 

SHELIA L. THORNE 

19 

19 

19 



Health and Economic Toll of Under- and Uninsured Groups in South 

Carolina and Beyond: Can We Afford Not to Insure Everyone? 



• Describe the financial burden of uncontrolled hypertension 

• Explain the cost of hypertension prevention and control vs treatment of the outcomes 


Healthcare Access 







President’s Recognition and 

Awards Ceremony Reception 

5:30 PM to 6:30 PM 


Welcome 




ISHIB Vice President 

SHAWNA D. NESBITT, MD, MS 

20 

20 

20 

Presentation to Award Recipients 











and Risk Reduction in African American 

Patients with Metabolic Syndrome: 

What are the Best Approaches? 



• List the components of the metabolic syndrome and how these components 

manifest uniquely in African American patients 

• Outline how biomarkers are used to determine risk of cardiovascular disease 

• Using a case-based model, define the utility of antihypertensive combinations to 

manage hypertension in African American patients with both hypertension and 

metabolic syndrome, and describe novel approaches used to assess vascular 

status 

6:30 PM to 8:30 PM 


CME: 2.0 CEU: .2 

Chair 


Faculty 

JAMES R. SOWERS, MD 


21 

21 

21 

Welcome/Overview 


Components of the Metabolic Syndrome in African American Patients 



Inflammatory Markers in Cardiovascular Disease 


Combination Therapy in African Americans with Hypertension and 

Metabolic Syndrome: What Are the Best Choices? 


Faculty Panel Discussion. Cases in Point: Addressing the Challenges in 

African American Patients with Hypertension and Metabolic Syndrome 







This activity is supported by an 

independent educational grant 

from Daiichi Sankyo, Inc.

22 

22 

22 


How to Become 

More Involved 

in ISHIB 

Come have breakfast with three ISHIB 

Board of Trustee members and learn 

more about ISHIB and the activities 

the organization is involved in. Learn 

how you can become a member or 

more active in some of the projects 

and initiatives of the organization. 

W. DALLAS HALL, MD 

ISHIB FOUNDER 

7:30 AM to 8:30 AM 


Faculty 

W. DALLAS HALL, MD 




ISHIB FOUNDER 


ISHIB VICE PRESIDENT 




Plenary Session II 

Diabetes: New Age - Is it Beneficial 

or Harmful? 



• Explain the association between lipid levels and cardiovascular disease risk in 

Black populations 


KWAME OSEI, MD 


017 - Efficacy of An Amlodipine/Olmesartan Medoxomil-Based Titration 

Regime in Black or Non-Black Patients with Hypertension 

DEAN KEREIAKES 

Glycemic Targets and Cardiovascular Outcomes: 

From UKPS, VADT, ADVANCE to ACCORD 

DAVID M. KENDALL, MD 


• Review the recent findings of the UKPDS 10-year follow-up, VADT, ADVANCE 

and ACCORD trials 

• Discuss the impact of glucose control on complications risk in type 2 diabetes 

• Outline a rational approach to comprehensive risk factor management, including 

glucose control, in type 2 diabetes 

Management of Hypertension in African Americans with Diabetes 

JAMES W. REED MD 


• Understand the prevalence of hypertension and type 2 diabetes 

• Explain the pharmacological approach to treating hypertension in African 

Americans with type 2 diabetes 

• Appreciate the value of aggressively treating hypertension in diabetes 

Management of Lipids in African Americans 

ANNE E. SUMNER, MD 


• Appreciate ethnic differences in the association between TG levels and cardiovascular 

risk 

• Recognize the potential for cardiovascular risk of low HDL-cholesterol levels occurring 

in the absence of elevated TG levels 

• Report on how the lipid profile is changing in African populations with progressive 

urbanization 



TRUDY GAILLARD, PHD, MS, RN 

8:30 AM to 10:00 AM 


CME: 1.5 CEU: .15 

Co-Chairs 



Faculty 








23 

23 

23 


Exhibition and Abstract Poster Sessions 

and Industry Expert Theater 

10:00 AM – 11:30 AM 

Merit Posters 

10:00 AM to 11:30 AM 

2:30 PM to 3:30 PM 

4:30 PM to 6:30 PM 


004 - Effect of Nebivolol in Obese African American Patients with 

Hypertension 

KEITH FERDINAND 

24 

24 

24 

005 - Ethnic Differences in Response to Initial Treatment with Valsartan 

Monotherapy or Combination Valsartan/Hydrochlorothiazide in Patients with 

Stage 2 Hypertension 

JOHN FLACK 

016 - The Combination of Amlodipine + Olmesartan Medoxomil Provides 

Numerically Greater Reductions in Blood Pressure Compared with 

Component Monotherapies in Race and Ethnic Subgroups 

SUZANNE OPARIL 

2:30 PM – 3:30 PM 

Merit Posters 

007 - Changes in Glutathione Metabolism in Hypertensive African American 

Women 

ZHONG MAO GUO 

015 - Impact of Race on BP Reduction and Goal Achievement of 

Olmesartan Medoxomil-Based Treatment in Patients with Type 2 Diabetes 

JOEL NEUTEL 

021 - The Metabolic Syndrome Does Not Effectively Identify Diabetes Risk in 

Black Africans: Results of a Pilot Comparison of Black Africans and African 

Americans 

ANNE SUMNER 

Industry Expert Theater 


KEITH NORRIS, MD, CONFERENCE CO-CHAIR AND ISHIB BOARD MEMBER 

5:00 PM to 6:00 PM 


AZOR®: For the Treatment of Hypertension in African American Patients 

amlodipine and olmesartan medoxomil 

Presented by Daiichi Sankyo, Inc 

Bystolic®: For the Treatment of Hypertension 

Presented by Forest Laboratories, Inc. 


KEITH NORRIS, MD 




Lunch Symposium 

Glycemic Targets in Patients with Type 2 

Diabetes: A New Era? 



• Recognize issues related to hypoglycemic risk in patients with type 2 diabetes 

• Summarize current targets for effective management of type 2 diabetes and 

hypertension 

• Apply a case-based approach to manage cardiovascular risk, including risk possibly 

associated with hypoglycemia, in patients with type 2 diabetes and hypertension 

in the clinical setting 

11:30 AM to 1:30 PM 


CME: 2.0 CEU: .2 

Chair 


Faculty 



25 

25 

25 



Hypoglycemic Targets: Interpreting Latest Trial Evidence 



Managing CV Risk in African Americans with Type 2 Diabetes and 



Faculty Panel Discussion. Managing Risk in an African American 

Patient with Hypertension and Diabetes: A New Era? 








from Takeda Pharmaceuticals 

North America, Inc.

Annual Members’ Meeting 

KENNETH A. JAMERSON, MD, ISHIB PRESIDENT 

AND SHAWNA D. NESBITT, MD, MS, ISHIB VICE PRESIDENT PRESIDING 

1:30 PM to 2:30 PM 




ISHIB Vice President 


26 

26 

26 






Workshop C 

Understanding Genomics: 

Basics and Beyond 



• Explain human genetic variation and how it is measured 

• Identify molecular technologies for detecting genetic variation 

• Discuss case studies of genetic association studies of CVD in African Americans 

3:30 PM to 4:30 PM 


CME: 1.0 CEU: .1 

Chair 

RICK A. KITTLES, PHD 

Faculty 

JOHN CARPTEN, PHD 

JAMES WILSON, MD 

27 

27 

27 



An Update on Genomic Profiling: New Technologies 

and Methodologies 

JOHN D. CARPTEN, PHD 


• Explain genomic profiling and its benefits to medicine 

• Identify novel technologies and methodologies including next generation sequencing 


Ancestry, Genetic Association and Hypertension 



• Review the significance of African ancestry and ancestral admixture in the genetics 

of common complex diseases of African Americans 

• Discuss admixture mapping of genetic loci that affect phenotypes of interest 

• Review findings of possible admixture association with hypertension 

JOHN D. CARPTEN, PHD 





28 

28 

28 

 

Workshop D 

Heart Failure 



• Report on minority inclusion in heart failure trials 

• Review the clinical presentation, treatment and prognosis of systolic and diastolic 

heart failure 

• Review the epidemiology of heart failure in minority populations 

• Discuss the differences in clinical presentation and outcome of heart failure in 

minority populations 

3:30 PM to 4:30 PM 


CME: 1.0 CEU: .1 

Chair 

ANEKWE E. ONWUANYI, MD 

Faculty 

ILEANA L. PIÑA, MD 



Comparison of Heart Failure in the Minority Populations 

ILEANA L. PIÑA, MD 


• Review differences in prevalence and presentation of heart failure in minority 

populations 

• Present outcome differences in minority populations with heart failure 


Systolic and Diastolic Heart Failure 



• Define systolic and diastolic heart failure 

• Discuss the clinical presentation of systolic and diastolic heart failure 

• Review the results of major clinical trials on heart failure 

• Compare the treatment and prognosis of systolic and diastolic heart failure 







Oxidative Stress, Endothelial Function 

and Beta Blockade in Hypertensive 

Disease: A Fresh Look at African American 

Patients 



• Describe the links between oxidative stress, endothelial function, and hypertensive 

disease progression 

• List the latest findings describing the effect of beta blockade on mechanisms of 

hypertensive disease progression 

• Address the preexisting myths surrounding use of beta blockade in African American 

patients using an evidence-based approach 

• Using a case-based model, discuss the appropriate role for beta blockade in 

management of elderly African American patients with both hypertension and 

angina 

6:30 PM to 8:30 PM 


CME: 2.0 CEU: .2 

Chair 


Faculty 

GARY H. GIBBONS, MD 

ELIZABETH OFILI, MD, MPH 

29 

29 

29 



Oxidative Stress, Endothelial Function, and Beta Blockade: Newest 

Findings 



Hypertensive Disease Management in African Americans: Interpreting 

the Role of Beta Blockade 


Faculty Case Discussion. An Elderly African American Patient with 

Hypertension and Angina 









from Forest Laboratories, Inc.


Ask the Experts, 

A Discussion 

of Practical 

Case Studies 

7:30 AM to 8:30 AM 


Faculty 


DAVID S. KOUNTZ, MD 


30 

30 

30 

Come join our expert panel as they 

present practical case studies. Cases 

will be discussed from an internal 

medicine, cardiology, and nephrology 

point of view by our expert panel representing 

their respective specialties. 


DAVID S. KOUNTZ, MD 





Plenary Session III 

Chronic Kidney Disease: Early Diagnosis 

and Halting the Progression 



• Review the staging classification of chronic kidney disease (CKD) 

• Discuss the importance of early detection of CKD 

• Review the cardiovascular implications of CKD 

• Review the important role of hypertension in CKD 

8:30 AM to 10:00 AM 


CME: 1.5 CEU: .15 

Chair 

JANICE P. LEA, MD 

Faculty 

SUSANNE B. NICHOLAS, 

MD, PHD, MPH 

31 

31 

31 




023 - Relationship between Inflammation and Hypertension in Blacks 

RALPH WATSON 


Chronic Kidney Disease Staging: The Pros and Cons 

SUSANNE B. NICHOLAS , MD, PHD, MPH 


• Describe current evaluation and classification of renal function 

• Describe arguments against the current staging of chronic kidney disease (CKD) 

• Describe arguments for the current staging of CKD 

• Provide a plausible new approach to CKD staging 

Management of Hypertension in the CKD Patient 



• Review the pathophysiology of hypertension in CKD 

• Discuss new treatment options to delay progression of hypertensive kidney 

disease 

SUSANNE B. NICHOLAS, 

MD, PHD, MPH 





and Abstract Poster Sessions 

10:00 AM – 11:00 AM 

Merit Posters 

10:00 AM to 11:00 AM 

Noon to 12:30 PM 


32 

32 

32 

002 - Blood Pressure and Hypertension among 

Dutch Africans, South Asians, British Africans and 

South Asians: A Cross National Comparative Study 

CHARLES AGYEMANG 

025 - Faith-Based DASH Lifestyle Program for 

Hypertension Control in African American Church 

Communities- Program Overview 

SUNITA DODANI 


Merit Poster 

001 - Diabetes and Stroke Hospitalized Patients in 

2006: An Analysis of Healthcare Cost by Race and 

Gender 

BAQAR HUSAINI 




Workshop E 

Treatment of Anemia and Metabolic 

Derrangements and Chronic Kidney 

Disease: What is Appropriate 

and What is Not 



• Explain the importance of evaluating and treating anemia in CKD 

• Describe the relationship between anemia and CVD in patients with CKD 

• Illustrate the relationship between certain CVD risk factors and CKD 

• Recognize the impact of treating certain CVD risk factors on progression of CKD 



CME: 1.0 CEU: .1 

Co-Chairs 


EDDIE L. GREENE, MD 

Faculty 

R. MICHAEL CULPEPPER, MD 

J. KEVIN TUCKER, MD 

33 

33 

33 




Treatment of Anemia in CKD: Impact on CVD 



• Describe mechanisms leading to anemia in patients with chronic kidney disease 

(CKD) not on dialysis 

• Recall the progression of the stages of CKD as related to progressive cardiovascular 

disease (CVD) and increasing patient mortality 

• Recount the relationship between anemia and the occurrence of left ventricular 

hypertrophy (LVH) as a risk factor for cardiovascular disease and death in 

patients with CKD 

• Describe the basic evaluation of patients with CKD and anemia and applicable 

treatment in the outpatient setting 

Impact of Treating Elevated Lipids, Glucose, and Inflammatory 

Markers on CKD 

J. KEVIN TUCKER, MD 


• Recognize the impact of hyperlipidemia on CKD and the impact of CKD on 

hyperlipidemia 

• Identify the role of lipid-lowering therapy in CKD 

• Explain the impact of hyperglycemia on CKD 








J. KEVIN TUCKER, MD

Workshop F 

Vitamin D and Chronic Diseases 


To be announced 



CME: 1.0 CEU: .1 

Co-Chairs 


Faculty 

DIANE E. WALLIS, MD 

34 

34 

34 



Vitamin D Overview- What Clinicians Need to Know 



• Identify the pathophysiology of vitamin D deficiency and secondary hyperparathyroidism 

with a focus on the etiology of hypertension in African Americans 

• Describe how to diagnose and treat vitamin D deficiency 


Vitamin D and Chronic Kidney Disease 








Lifestyle Modification Workshop 



• Identify the structural and process elements of clinical practice that affect selfmanagement 

and adherence to lifestyle prescriptions 

• Identify the three key elements of self-management support 

• Discuss practical methods of creating system triggers for lifestyle interventions 

• Explore the influence of the providers’ cultural competence on adherence behaviors 

• Examine how the patient’s perspective of the provider and provider prescriptions 

affects adherence 

12:30 PM to 2:00 PM 


CME: 2.0 CEU: .2 

Chair 

ROSALIND M. PETERS, PHD, RN 

Faculty 

TIMOTHY J. LONG, MD 

DEBRA J. BARKSDALE, PHD, RN, FNP 

RAMONA BENKERT, PHD, RN 

35 

35 

35 

Introduction: Improving Adherence and Self-Management within the 

Chronic Care Model 



• Identify factors that promote self-management and the delivery of clinical care 

that is consistent with scientific evidence and patient preferences 

• Identify the six key elements in the chronic care model 


Office System Factors Affecting Adherence: 

Decision-Support Mechanisms 

TIMOTHY J. LONG, MD 


• Identify decision support techniques that can be used to improve patient selfmanagement 

• Explore current research related to the effect of system decision support on patient 

outcomes 

• Discuss practical methods of integrating decision support mechanisms within 

existing office practices 


Provider Factors Affecting Adherence: Cultural Competency 

and Sensitivity 

DEBRA J. BARKSDALE, PHD, RN, FNP 


• Compare and contrast cultural competency and cultural sensitivity 

• Discuss the idea of cultural competency in race-concordant and race-discordant 

patient-provider relationships 

• Discuss practical methods of integrating cultural competence strategies into the 

realities of a provider’s practice 

DEBRA J. BARKSDALE, 

PHD, RN, FNP 

36 

36 

36 

Patient Factors Affecting Adherence: Empowering Patients 

for Self-Management 



• Describe the role of trust in the provider as it relates to patient adherence to 

provider prescriptions 

• Discuss how the patient’s own attitudes, beliefs and health system history influences 

adherence and empowerment 

• Discuss lessons learned in working across similarities and differences in race, 

ethnicity, socioeconomic status, and sexual orientation that can enhance trust 

and “buy in” from the patient 






PartThree 

Faculty

38 

38 

38 

GEORGE L. BAKRIS, MD - P 13 

Professor of Medicine 

Director Hypertensive Diseases Unit Section 

of Endocrinology, Diabetes and Metabolism 

University of Chicago - Pritzker School of Medicine 

5841 S. Maryland Avenue, MC 1027 

Chicago, Illinois 60637 

Dr. Bakris is a professor of medicine and the director of 

the Hypertensive Diseases Unit in the Section of Endocrinology, 

Diabetes and Metabolism at the University of Chicago-Pritzker 

School of Medicine. He has published more than 450 articles 

and book chapters in the areas of kidney disease, hypertension 

and the progression of nephropathy. He has also served on many 

national committees including the JNC-7 executive and writing 

committees, the ADA practice guideline committee (2002-2004), 

and the National Kidney Foundation’s hypertension and diabetes 

guideline committee. Dr. Bakris is also the past-president of the 

American College of Clinical Pharmacology (2000-2002) and 

the president-elect of the American <strong>Society</strong> of Hypertension. He 

is the current editor of Am J Nephrology and the Hypertension 

Section editor of Up-to-Date. 

Has received grant support from NIH(NIDDK), Glaxo-SmithKline, Forest, 

Juvenile Diabetes Foundation. Serves as: a consultant for Abbott, Takeda, 

Glaxo-Smith Kline, Boerhinger-Ingelheim, Gileada, Novartis, Merck; member of 

speaker’s bureau for Novartis, Forest; scientific advisory board member for Abbott, 

Boerhinger-Ingelheim, Forest, Merck, Novartis, Walgreens (formulary committee), 

Gilead, Diachii-Sankyo. 

DEBRA J. BARKSDALE, PHD, RN, FNP 1 - P 35 

Assistant Professor of Nursing 

School of Nursing 

University of North Carolina at Chapel Hill 

Carrington Hall, CB #7460 

Chapel Hill, North Carolina 27599 

Dr. Barksdale is a nurse practitioner, educator and researcher 

with more than 20 years of experience in urgent, primary and 

home care. She holds degrees from the University of Virginia and 

Howard University, a post-master’s certificate from the University 

of Pennsylvania, and a PhD from the University of Michigan. 

She practices at the Robert Nixon Clinic and has a funded NIH 

research grant: Hypertension in Black Americans: Environment, 

Behavior, and Biology. 

RAMONA BENKERT, PHD, RN 1 - P 35 

Associate Professor 

College of Nursing 

Wayne State University 

5557 Cass Avenue, 370 Cohn Building, Rm 370 

Detroit, Michigan 48202 

Dr. Ramona Benkert is an associate professor at Wayne 

State University. Dr. Benkert’s research focuses on cross-cultural 

primary care relationships and outcomes in primary care. Dr. 

Benkert serves on several healthcare advisory boards. She has 

been involved in outcome evaluations in primary care settings 

and has practiced as a primary care provider for more than 20 

years. 

ANGELA L. BROWN, MD - P 13 

Assistant Professor of Medicine 

Washington University in St. Louis 

School of Medicine 

Cardiovascular Division 

660 S. South Euclid Ave, Box 8086 

St. Louis, Missouri 63110 

Dr. Brown is an assistant professor of medicine at the Washington 

University School of Medicine. She currently serves as the 

director of the Section of Hypertension in the Division of Cardiology. 

Her clinical practice focuses on the management of patients 

with high blood pressure with or without complications. Her research 

interest is in the area of hypertension and its relationship 

to other comorbidities, particularly diabetes and left ventricular 

dysfunction. Dr. Brown was recognized by the St. Louis American 

as one of the Outstanding Physicians in St. Louis in 2004, and 

received an outstanding service award from the Minority Health 

Council of the American Heart Association, St. Louis Affiliate. 

Has received grant support from NIH. Serves on the speaker bureau 

for Boehringer Ingelheim, Bristol-Myers Squibb Co., Forest Laboratories, 

GlaxoSmithKline, and Novartis Pharmaceuticals. 

JOHN D. CARPTEN, PHD 1 - P 27 

Senior Investigator & Director 

Translational Genomics Research Institute (TGen) 4 

45 N. 5th Street 

Phoenix, Arizona 85004 

John D. Carpten, PhD is a member of the TGen team, 

having previously served as an intramural tenure track 

investigator with the Cancer Genetics Branch of the National 

Human Genome Research Institute (NHGRI), NIH, a group that 

pioneered a number of innovative technologies and methods to 

study the underlying genetics of cancer. While a fellow and later 

a tenure track investigator at NHGRI/NIH, he co-led the first 

published genome wide scan for prostate cancer susceptibility 

genes (Science, 1996). Dr. Carpten also has an intense focus on 

understanding the role of genetics in prostate cancer incidence 

and mortality disparities seen among African American men. 

Through his leadership, the African American Hereditary Prostate 

Cancer Study (AAHPC) Network has become a model for genetic 

linkage studies in underrepresented populations and led to the 

first genome wide scan for prostate cancer susceptibility genes 

in African Americans. More recently, his group has discovered 

a number of single nucleotide polymorphisms, which confer 

increased risk of developing prostate cancer. He has recently 

led and co-authored a series of articles describing the roles of 

genetic variants in prostate cancer risk in Genome Research, 

Journal of the National Cancer Institute and the New England 

Journal of Medicine. 

FacultyAbstractsExhibitorsSupporters 

1 

Has no financial or other relationships to disclose. 2 Will disclose any financial or other relationships in session.



ERROL D. CROOK, MD 1 - P 13, 33 

Abraham A. Mitchell Chair 

Department of Internal Medicine 

University of Alabama College of Medicine 

2451 Fillingim Street, Mastin 400A 

Mobile, Alabama 36617-2293 

Errol D. Crook, MD is Abraham A. Mitchell professor and 

chair, Department of Internal Medicine, and interim director, 

Center for Healthy Communities, University of South Alabama 

College of Medicine in Mobile, Alabama. Before moving to 

Mobile in June 2005, Dr. Crook was on faculty at Wayne State 

University School of Medicine / Detroit Medical Center in Detroit, 

MI where he served as chief of medicine at Harper University 

Hospital and as acting chair of the Department of Internal Medicine. 

Dr. Crook is past-president of the American Federation for 

Medical Research and is a member of several scientific organizations 

and editorial boards. His research focus is in health disparities 

with a special interest in diabetes, diabetic renal disease, 

hypertension and cardiovascular disease in health disparate 

populations. He is the principal investigator of a National Center 

of Excellence Grant from the NIH’s National Center for Minority 

Health and Health Disparities. 

R. MICHAEL CULPEPPER, MD - P 33 



University of South Alabama College of Medicine 

2451 Fillingim Street, Mastin Office Bldg, 5th Fl 

Mobile, Alabama 36617-2293 

Dr. Culpepper, a native of Alabama, trained in nephrology 

at the University of Alabama in Birmingham and, since 1992, has 

served as director of nephrology and hypertension at the University 

of South Alabama in Mobile. He is an active clinical investigator 

and an ASH-certified clinical specialist in hypertension. 

Has received grant/research support from Amgen, Novartis Pharmaceuticals, 

and Otsuka Pharmaceuticals. Serves on the speaker bureau for Forest Laboratories 

and Novartis Pharmaceuticals. 

BRENT M. EGAN, MD - P 19 

Professor of Pharmacology and Medicine 

General Internal Medicine Hypertension Section 

Medical University of South Carolina 

135 Rutledge Avenue, RT 1004 

Charleston, South Carolina 29425 

Brent M. Egan, MD, professor of medicine and pharmacology 

at the Medical University of South Carolina, focuses his 

clinical and basic research on the mechanisms of cardiovascular 

risk in obesity. His current work in community activities includes 

the Hypertension Initiative, which includes ~1500 primary care 

providers and ~1,300,000 patients in the Southeast in an effort 

to improve cardiovascular health. The US Department of Health 

and Human Services recognized the Initiative as a national 

Best Practice Model in March 2004 and again in July 2004 for 

reducing health disparities. His numerous research activities have 

fostered more than 200 original papers and reviews and led 

to positions on the editorial boards of the American Journal of 

Hypertension, Current Hypertension Reports, Ethnicity and Disease, 

Hypertension, Journal of Human Hypertension, Therapeutic 

Advances in Cardiovascular Disease and Journal of the American 

Nutraceutical Association. 

Serves as a consultant for AstraZeneca and Novartis Pharmaceuticals. Serves 

on the speaker bureau for Novartis Pharmaceuticals. 

KEITH C. FERDINAND, MD - P 15, 21, 25, 30 

Clinical Professor, Cardiology Division 

Emory University 

Chief Science Officer 

Association of Black Cardiologists 

5355 Hunter Road 

Atlanta, Georgia 30349 

Keith C Ferdinand, MD, is the chief science officer for the 

Association of Black Cardiologists, as well as the director of 

their Hurricane Katrina Relief effort, known as the HOPE (Health 

Outreach and Empowerment) Initiative. He is also a clinical 

professor, Cardiology Division Department of Medicine at Emory 

University in Atlanta, and an adjunct clinical professor, Department 

of Medicine at the Morehouse School of Medicine, also 

in Atlanta. Previously, Dr. Ferdinand was the medical director 

of Heartbeats Life Center and professor of Clinical Pharmacology 

at Xavier University College of Pharmacy in New Orleans, 

Louisiana. Dr. Ferdinand currently serves as the principal 

investigator of the Healthy Heart Community Prevention Project, 

a cardiovascular risk program that targets African American and 

other high-risk populations. Dr. Ferdinand was a member of the 

ALLHAT Data Safety and Monitoring Board and chair of Section 

Four of the Sixth Report of the Joint National Committee. He 

was a member of the Ad Hoc Committee on Minority Populations 

for the National Heart Lung and Blood Institute (NHLBI) 

and a member of the National High Blood Pressure Education 

Program Coordinating Committee. He was director of the NHLBI 

Physician’s Health Network, a program that educated physicians 

and the lay population on cardiovascular risk reduction. He is 

past president and former member of the Louisiana State Board 

of Medical Examiners, past president of the Orleans Division of 

the American Heart Association, and past chair of the Board of 

Association of Black Cardiologists, Inc. 

Serves as a consultant for AstraZeneca, Daiichi Sankyo, Roche, and Sanofi. 

Serves on the speaker bureau for AstraZeneca and Sanofi. 

JOHN M. FLACK MD, MPH - P 13 

Chair, Department of Medicine 

Wayne State University School of Medicine 

4201 Street Antoine, 2E-UHC 


Dr. John Flack, author of more than 150 publications and 

a graduate of the University of Oklahoma School of Medicine 

(1982), is professor and chairman of the Department of Medicine 

and chief, Division of Translational Research and Clinical 

Epidemiology at Wayne State University. 

Has received grant support from Astra Merck Human Health, AstraZeneca, 

CardioDynamics, Centers for Disease Control (CDC), Daiichi Sankyo, 

GlaxoSmithKline, Merck, Mannheim, National Institutes for Health (NIH), Novartis 

Pharmaceuticals, Pfizer. Serves as a consultant for Bristol-Myers Squibb Co., CardioDynamics, 

Centers for Disease Control (CDC), CVRx, GlaxoSmithKline, Merck, 

Myogen, Novartis Pharmaceuticals, and National Institutes for Health (NIH). Serves 

on the speaker bureau for Daiichi Sankyo, Novartis Pharmaceuticals, and Pfizer. 

39 

39 

39 


1 


40 

40 

40 

TRUDY GAILLARD, PHD, RN, MS 1 - P 23 

Program Director 

The Ohio State University 

Division of Endocrinology, Diabetes & Metabolism 

6863 Gray Galdes Lane 

Columbus, Ohio 43235 

Dr. Gaillard serves as an assistant professor of research in 

the Division of Endocrinology, Diabetes and Metabolism at the 

Ohio State University Medical Center. Dr. Gaillard’s research 

interests include lifestyle interventions aimed at preventing type 2 

diabetes and cardiovascular disease in African American women. 

She is also interested in the metabolic correlates that lead to increased 

cardiovascular disease mortality and diabetes in African 

American women. 

GARY H. GIBBONS, MD 1 - P 29 

Gary H. Gibbons, MD is the endowed Director of the 

Morehouse Cardiovascular Research Institute, a Professor of 

Medicine and Chairman of the Department of Physiology. 

He also serves as Program Director of the Center of Clinical 

Research Excellence and the NIH T-32 Training Program in 

Cardiovascular Science. Dr. Gibbons is a board-certified 

cardiologist with research training expertise in molecular 

vascular biology. He earned his undergraduate degree from 

Princeton University and graduated magna cum laude from 

Harvard Medical School in Boston. He completed his residency 

and cardiology fellowship at the Harvard-affiliated Brigham 

& Women’s Hospital in Boston. His research mentors include: 

Victor Dzau, Thomas Smith, A. Clifford Barger and Eugene 

Braunwald. 

He has been selected as a Robert Wood Johnson 

Foundation Minority Faculty Development Awardee, a Pew 

Foundation Biomedical Scholar, an Established Investigator of the 

American Heart Association (AHA) and was recently elected as 

member of the Institute of Medicine of the National Academy of 

Sciences. Dr. Gibbons was a member of the faculty at Stanford 

University (1990-1996) and Harvard Medical School (1996- 

1999) before becoming the founding Director of the Morehouse 

Cardiovascular Research Institute in July 1999. He serves on 

several editorial boards for journals in cardiovascular medicine 

as well as advisory boards and grant review committees for the 

NIH, Juvenile Diabetes Foundation and the AHA. 

Dr. Gibbons directs NIH-funded research in the fields of 

vascular biology, genomic medicine and the pathogenesis of 

vascular diseases and ranks in the top 5% in the receipt of NIH 

funding. The innovations derived from his research have resulted 

in the receipt of several US patents. His bibliography lists over 

80 reviews and original reports in the fields of vascular biology, 

gene therapy, hypertension, atherosclerosis, genomics, health 

disparities research and cardiovascular medicine. Dr. Gibbons 

maintains a passionate commitment to expanding the gender 

and ethnic diversity of biomedicine as well as the elimination of 

health disparities. He is married with three children and resides in 

Atlanta, Georgia. 

EDDIE L. GREENE, MD 1 - P 33 


Nephrology Division, Mayo Clinic 

200 1st Street, SW Eisenberg S-24 

Rochester, Minnesota 55905 

Eddie L. Greene, MD is associate professor of medicine at 

Mayo Medical School and the director of the Office for Diversity 

in Education in the College of Medicine at Mayo Clinic in 

Rochester, Minnesota. He serves as a Mayo Clinic consultant 

physician in the Division of Nephrology and Hypertension. 

Dr. Greene is chair of the Mayo Clinic CTSA (Clinical and 

Translational Science Award) Health Disparities Initiative. 

Dr. Greene’s research led to the identification of 

mechanisms contributing to renal fibrosis, glomerulosclerosis, 

and the development of atherosclerotic cardiovascular disease 

in patients with chronic kidney disease. His current clinical and 

research interests include health disparities in chronic kidney 

disease and the identification of new clinical interventions 

designed to slow the progression of chronic kidney disease and 

its associated cardiovascular co-morbidities. 

Dr. Greene is a lifetime member of ISHIB, previous Robert 

Wood Johnson-Harold Amos Medical Faculty Development 

Awardee, and a founding member of the NIH-NIDDK Network of 

Minority Research Investigators (NMRI). 

W. DALLAS HALL, MD 2 - P 22 

Professor Emeritus 

Emory University School of Medicine 

W. Dallas Hall, MD, MACP is an emeritus professor of 

Emory School of Medicine, where he served as professor from 

1976-1997. He graduated magna cum laude from Emory 

University School of Medicine and completed a residency in 

internal medicine at Grady Hospital. He was co-director of the 

Division of Nephrology from 1973-1976, director of the Division 

of General Medicine from 1982-1985; director of the Division of 

Hypertension from 1976-1997. He has also served as program 

director of the Clinical Research Center from 1988-1997. Dr. 

Hall is a founding member of ISHIB and is an associate editor 

for Ethnicity & Disease. He also holds memberships in AHA, ASH, 

AFCR, ASCPT, COSEHC, SSCI and ACP. He has authored four 

textbooks, 77 book chapters, and 119 manuscripts 


1 




KENNETH A. JAMERSON, MD - P 15, 20, 26, 29 

Professor of Internal Medicine 

University of Michigan 

Cardiovascular Medicine 

24 Frank Lloyd Wright Drive 

Lobby M, 3rd Fl Domino Farms 0739 

P.O. Box 322 

Ann Arbor, Michigan 48106 

Kenneth A. Jamerson, MD, is professor, Division of Cardiovascular 

Medicine, University of Michigan Medical School 

and medical director of the Program for Multicultural Health, 

University of Michigan Health System, Ann Arbor, Michigan. Dr. 

Jamerson is an advisor to national and international clinical 

trials that examine the impact of hypertension control on global 

populations. Dr. Jamerson is the current president of ISHIB, an 

international organization devoted to ethnicity and disease. His 

research includes addressing the perceptions, barriers and behaviors 

that may affect healthcare disparity. In a novel investigation, 

Dr. Jamerson, with investigators from the Institute for Social 

Research at the University of Michigan, describes how these 

factors affect African American’s participation in clinical trials. 

He is part of a multi-disciplinary team using cognitive theory 

for behavior modification strategies. The first study of its kind, 

it resulted in participants’ long-term loss of weight, decrease in 

blood pressure, and lowered cholesterol levels, with the benefits 

persisting for nearly a year after the initial intervention. 

Has received grant/research support from King Pharmaceuticals, NIDDK, 

NIH, Novartis Pharmaceuticals. Serves as a consultant for Daiichi Sankyo, Merck, 

Novartis Pharmaceuticals. Serves on the speaker bureau for Daiichi Sankyo, 

Novartis Pharmaceuticals. 

DAVID M. KENDALL, MD - P 23, 25 

Medical Director and Chief 

Clinical and Professional Services 

<strong>International</strong> Diabetes Center 

University of Minnesota 

3800 Park Nicollet Boulevard 

Minneapolis, Minnesota 55416 

Dr. David Kendall is the medical director and chief, Clinical 

and Professional Services at the <strong>International</strong> Diabetes Center 

(IDC) in Minneapolis, Minnesota. Dr Kendall holds an appointment 

as associate professor of medicine at the University of 

Minnesota Medical School. He also serves as an investigator 

in numerous government, foundation and industry-sponsored 

clinical trials including a role as principal investigator for the NIH 

ACCORD trial and the landmark DCCT/EDIC study. An active 

diabetes researcher, educator and clinician since 1990, Dr. 

Kendall has published more than 150 original articles, chapters, 

professional reviews and published abstracts. He remains active 

in both medical education and research – with clinical and research 

interests focused on the management of both type 1 and 

type 2 diabetes, emerging and novel therapies for diabetes care, 

the treatment and prevention of cardiovascular complications of 

diabetes, and studies of models of diabetes care delivery. 

Has received grant/research support from Abbott Diabetes Care, Amylin 

Pharmaceuticals, Bayer Diabetes Care, Dexcom, Eli Lilly and Co, MannKind, 

Merck, Minimed-Medtronic, NIH-NHLBI, Novo Nordisk, ResMed, Roche, Sanofi- 

Aventis. Serves as a consultant for Amylin Pharmaceuticals, CV Therapeutics, Daiichi-Sankyo, 

Eli Lilly and Co., HeatlhPartners, Intarcia, Nektar Therapeutics, Roche, 

Takeda. 

RICK A. KITTLES, PHD 1 - P 27 


Section of Genetic Medicine 

University of Chicago Section of General Medicine 

5841 S. Maryland Avenue 


Dr. Rick Kittles is an associate professor in the Section of 

Genetic Medicine, Department of Medicine and associate 

director for Diversity and Community Relations at the University 

of Chicago Cancer Research Center. He has published on the 

influence of genes and environment on sudden infant death 

(SIDs) in African Americans and has been at the forefront of the 

development of ancestry-informative genetic markers, admixture 

mapping theory, and applications for disease gene mapping in 

admixed populations, such as African Americans and Hispanics. 

Dr. Kittles’ high profile research and his strong ability to communicate 

genetic concepts and issues eloquently and understandably 

to the lay public has been featured during the past decade 

in five PBS and BBC network documentaries related to human 

biological diversity, race and disease. His work has been featured 

on CNN and 60 Minutes where he was interviewed by Leslie 

Stahl. Dr. Kittles has published more than 60 articles and book 

chapters on race, health disparities and the genetics of complex 

traits and disease in the African American population. 

MYRA A. KLEINPETER, MD - P 18 

Tulane University School of Medicine 

Section of Nephrology 

1430 Tulane Avenue, SL-45 

New Orleans, Louisiana 70112 

Dr. Myra Kleinpeter is an associate professor of Clinical 

Medicine at Tulane University in New Orleans, and director of 

the Tulane Peritoneal Dialysis program for Dialysis Clinics, Inc. 

She is also clinical lead for the Renal Beginnings Program at 

the Medical Center of New Orleans. As a member of the Board 

of Trustees of the American Kidney Fund, she serves as chair of 

Medical Affairs. She is a member of several professional organizations 

focusing on nephrology and hypertension. 

Serves on the speaker bureau for Boehringer Ingelheim, Forest Laboratories, 

and Pfizer. 

41 

41 

41 


1 


42 

42 

42 

DAVID S. KOUNTZ, MD 2 - P 30 

Associate Professor and Associate Dean 

UMDNJ - Robert Wood Johnson Medical School 

Jersey Shore University Medical Center 

1945 State Route 33 

Neptune, New Jersey 07754-0397 

Dr. David Kountz is senior vice president, Medical and 

Academic Affairs, Jersey Shore University Medical Center 

(JSUMC), and associate professor of medicine and associate 

dean, Robert Wood Johnson Medical School, New Brunswick. 

He is also a senior fellow in the School of Population Health, 

Jefferson Medical College, Philadelphia. In his role at JSUMC 

and Meridian Health, he is responsible for developing the 

academic strategic plan for the hospitals and overseeing 

undergraduate, graduate, and continuing medical education, as 

well as the Office of Research Services. 

Dr. Kountz’s clinical interests focus on hypertension, 

dyslipidemia and diabetes management in high-risk populations, 

as well as health literacy and health disparities. His research in 

these areas has been funded by the Pew Charitable Trust, the 

Centers for Disease Control and Prevention, and the American 

Group Medical Association. His most recent article on tolerability 

of beta-blockers in hypertension was published in the January 

2009 issue of Postgraduate Medicine. 

DANIEL T. LACKLAND, DRPH 1 - P 19 

Medical University of South Carolina 

Biometry and Epidemiology 

135 Cannon Street, 3rd Floor 

Charleston, SC 29425 

Daniel T. Lackland is professor, and director of Graduate 

Training and Education in the Department of Biometry and 

Epidemiology and the Division of Cardiology at the Medical 

University of South Carolina. He received his doctorate degree 

in cardiovascular epidemiology from the University of Pittsburgh. 

The past president of the Mid-Atlantic Affiliate of the American 

Heart Association, he is the current chair of the Diabetes 

Initiative of South Carolina. He also serves on the AHA Stroke 

Council Leadership Committee, Epidemiology and Prevention 

Council Leadership Committee, High Blood Pressure Research 

Committee Leadership Committee, and recently completed 

service on the AHA National Research Committee. Dr. Lackland 

was appointed in 2008 to the NHLBI Global Risk Assessment 

Workgroup, and the High Blood Pressure Guidelines (JNC 

8). He is the past-chairman of the South Carolina Stroke Task 

Force, Tri-State Stroke Network, and is the past president of the 

Carolinas-Georgia-Florida Chapter of the American <strong>Society</strong> of 

Hypertension. 

He is a member of the editorial boards of Hypertension, 

Journal of Clinical Hypertension, Journal of the CardioMetabolic 

Syndrome, Ethnicity and Disease, Journal of the American <strong>Society</strong> 

of Hypertension, and Preventive Medicine. He also leads blood 

pressure and risk factor screening activities at sporting events in 

the Southeast, and is a consultant for high blood pressure control 

programs in Latin America and central Asia. 

JANICE P. LEA, MD - P 31 

Associate Professor of Medicine 

Renal Division 

Emory University School of Medicine 

101 Woodruff Circle WMB Room 338 


Janice P. Lea, MD is board-certified in nephrology and 

hypertension.She serves on the advisory board for the United 

States Renal Data Systems and is the Emory principal investigator 

for the NIH study, African American Study of Kidney Disease and 

Hypertension (AASK). 

Dr. Lea is the national medical spokesperson for the 

National Kidney Disease Education Program (NKDEP), sponsored 

by NIH. Her research interests are in hypertension and kidney 

disease, and she has published many papers in this field. She is 

also active in her community, volunteering her time to educate 

susceptible populations about their risks of kidney disease due to 

hypertension and diabetes. 

Serves on the speaker bureau for Boehringer Ingelheim. 

TIMOTHY LONG, MD 1 - P 35 

Chief Clinical Officer 

Alliance of Chicago Community Health Services LLC 

1440 North Dayton Street, Suite 308 


Dr. Timothy Long serves as the chief clinical officer of the 

Alliance and is responsible for promoting and facilitating a cohesive, 

clinical leadership at the Alliance, fulfilling a vision of quality 

in alignment with Institute of Medicine dimensions and serving 

as the chief medical staff to support clinicians, research activities 

and end users. Dr. Long is a practicing internist at a partner 

community health center and specializes in public health, chronic 

disease management (diabetes, hypertension) and HIV/AIDS. He 

is a graduate of Loyola University of Chicago, Rush Medical College 

and completed his Primary Care/Internal Medicine training 

at John Stroger/Cook County Hospital. 

TERRY MASON, MD 2 - P 15 

Dr. Terry Mason is commissioner of the Chicago Department 

of Public Health. Appointed by Mayor Richard M. Daley, he is a 

leader of the Mayor’s Fitness Council and, in 2005, embarked on 

the mission to transform the department and make Chicago one 

of America’s healthiest cities. 

A credentialed urologist with specialization in prostate cancer 

and erectile dysfunction, Dr. Mason is a Fellow of the American 

College of Surgeons (FACS). He has served as chief of urology 

at Mercy Hospital and Medical Center and as assistant professor 

of urology at the Abraham Lincoln School of Medicine, University 

of Illinois (UICC). In 2000, he was national chair of the Urology 

Section of the National Medical Association. Presently, he serves 

on the faculty of the UICC School of Public Health 

Dr. Mason hosts a popular radio talk show, Doctor in the 

House, on WVON radio and is a frequent guest on television 

and radio programs including ESPN, He is a board member of 

the Saltpond Redevelopment Institute in Ghana, West Africa. His 

awards include Physician of the Year (1999) and a Telly Award 

for a video about prostate cancer entitled “Not By Myself.” He is 

a member of The American Urological Association, the National 

Medical Association, the American Medical Association and the 

Chicago Medical <strong>Society</strong>. 


1 




SHAWNA D. NESBITT, MD, MS 2 - P 20, 21, 22, 26 


Internal Medicine-Hypertension 

Medical Director 

Parkland Hypertension Clinic 

The University of Texas Southwestern 

Medical Center at Dallas 

5323 Harry Hines Blvd, CS8.102A 

Dallas, Texas 75390-8899 

Shawna D. (Smith) Nesbitt, MD, MS, is an associate professor 

in Internal Medicine-Hypertension at The University of Texas 

Southwestern Medical Center at Dallas. She serves as the medical 

director of the Parkland Hypertension Clinic. Her research 

interests include clinical trials and epidemiology of hypertension 

and cardiovascular risk. Her area of research is prehypertension, 

hypertension in African Americans, insulin resistance, and 

hyperlipidemia. Dr. Nesbitt is the national coordinator for the 

TROPHY Study (Trial of Prevention Hypertension). She is funded 

by the National Institutes of Health to study the relationship of 

oxidative stress and genetics in the development of hypertension. 

She is vice president for the <strong>International</strong> <strong>Society</strong> of Hypertension 

in Blacks (ISHIB). Dr. Nesbitt is a Fellow of the American Heart 

Association and the Council for High Blood Pressure Research. 

She also serves as an Advisory Panel member for the Red Dress 

Campaign sponsored by the National Institutes of Health. She 

is a member of the Childhood Obesity Healthcare Expert Panel, 

sponsored by American Heart Association and NIH. 

SUSANNE B. NICHOLAS, MD, PHD, MPH 2 - P 31 


Nephrology/Endocrinology Divisions UCLA 

900 Veteran Avenue, Suite 24-130 Box 957073 

Los Angeles, California 90095 

Dr. Susanne Nicholas is an associate professor of medicine 

and nephrologist at UCLA. Her translational research involves 

identification of susceptibility genes and their linkage relationships 

to diabetic nephropathy, therapeutic targets and drug delivery 

systems in chronic kidney disease using nanotechnology for 

ethnic populations. She is president of the NKF Medical Advisory 

Board of Southern California. 

KEITH C. NORRIS, MD - P 15, 30, 34 

Vice President, Office of Research 

Charles Drew University 

of Medicine & Science 

1731 E. 120th Street 

Los Angeles, California 90059 

Keith C. Norris, MD was recently appointed interim president 

of Charles Drew University of Medicine and Science in Los 

Angeles. He is also professor of medicine at the University and 

assistant dean for Translational Science at the Geffen School of 

Medicine at UCLA. He is a postdoctoral candidate in metaphysics, 

spirituality, and holistic health. He is board-certified by the 

American Boards of Internal Medicine and Nephrology, and certified 

as a Specialist in Clinical Hypertension by the American <strong>Society</strong> 

of Hypertension. In addition to serving as the editor-in-chief 

of the journal Ethnicity & Disease, Dr. Norris is also a reviewer for 

numerous journals and has written extensively for a wide variety 

of medical journals, textbooks, and consumer magazines with 

more than 175 peer-reviewed publications and book chapters. 

Presently, he serves on the Committee for Kidney Health in Disadvantaged 

Populations (CKHDP) under the Committee for the 

Global Advancement of Nephrology of the <strong>International</strong> <strong>Society</strong> 

for Nephrology. CKHDP promotes innovate strategies to improve 

the health of disadvantaged communities that suffer disproportionately 

from chronic kidney disease and its complications, with 

an emphasis on indigenous populations. In January 2009 he 

was selected as one of 25 Ambassadors for Research!America’s 

Paul G. Rogers <strong>Society</strong> for Global Health Research. 

Has received grant/research support from NIH. Serves as a consultant for 

Abbott Laboratories, Amgen, Monarch, and Pfizer. Serves on the speaker bureau for 

Abbott Laboratories, Amgen, Monarch, and Pfizer. 

ELIZABETH OFILI, MD, MPH 2 - P 29 

Elizabeth Ofili, MD, MPH is a Professor of Medicine and 

Chief of Cardiology at Morehouse School of Medicine and 

Director of the Clinical Research Center. Dr. Ofili has a unique 

combination of being an outstanding clinician investigator, 

matched with having an excellent scientific publication and 

grants track record. She completed medical school at Ahmadu 

Bello University in Nigeria and received her Master of Public 

Health at Johns Hopkins University. After completing her Internal 

Medicine Residency Program at Oral Roberts University, Ofili 

pursued her Cardiology Fellowship at Washington University and 

St. Louis University Health Science Center. 

Ofili has published over 100 scientific papers and has 

received several scientific research awards and honors. She has 

served on NIH and AHA study sections and review committees 

and on national research advisory committees; she currently 

serves on the AAMC Advisory Panel on Research. Under her 

outstanding leadership, the MSCR program has become the 

signature program at MSM for intensive training and education 

in clinical research. Under her guidance over the past five years 

the MSM CRC has begun to emerge as a nationally recognized 

leader in ethnic disparities clinical research. She is a co-PI of the 

Atlanta Clinical and Translational Institute (ACTSI). 

43 

43 

43 


1 


44 

44 

44 

ANEKWE E. ONWUANYI, MD - P 28 


Chief of Cardiology Medicine/Cardiology 

Morehouse School of Medicine 

720 Westview Drive S.W. 


Dr. Anekwe Onwuanyi serves as an associate professor of 

medicine and associate chief of cardiology at Morehouse School 

of Medicine. He is board-certified in cardiovascular diseases and 

is a consultant cardiologist at Grady Memorial Hospital, Atlanta 

Medical Center, Crawford Long Hospital and South Fulton Medical 

Center in Atlanta, Georgia. In addition to his clinical activities 

and teaching responsibilities, Dr. Onwuanyi is committed to 

researching methods to improve cardiovascular health disparities 

among African Americans. He is the principal investigator and 

co-investigator for several NIH-supported research projects in 

the area of hypertension, congestive heart failure and atherosclerosis. 

He is the current assistant editor for the ABC Digest of 

Urban Cardiology, and a reviewer for the Journal of the National 

Medical Association, Ethnicity and Disease, American Journal of 

Cardiology, Journal of Urban Cardiology and Circulation. 

Serves on the speaker bureau for CV Therapeutics and Novartis. 

KWAME OSEI, MD - P 23, 25 

Professor of Medicine and Exercise Physiology 

Ohio State University College of Medicine and Public Health 

Division of Endocrinology, Diabetes & Metabolism 

1581 Dodd Drive 

491 McCampbell Hall 

Columbus, Ohio 43210 

Kwame Osei, MD is a professor of medicine and the director 

of Division of Endocrinology, Diabetes and Metabolism and 

associate director for General Clinical Research Center at The 

Ohio State University College of Medicine and Public Health, 

Columbus, Ohio. Having received his medical degree from the 

University of Ghana Medical School, Dr Osei continued in a 

medical resident program at Hanemann Medical University in 

Philadelphia, and Temple University, Philadelphia, as well as a 

research fellowship in at Ohio State University College of Medicine. 

His research includes understanding of racial and ethic 

differences in glucose and substrate metabolism, energy expenditure 

and obesity with specific emphasis in African Americans and 

Blacks of West African Ancestry. Dr. Osei has received several 

national grants for his research and is a regular speaker at both 

national and international scientific meetings. He has been a 

member of several scientific committees at NIH and serves an 

advisory board member for several private pharmaceutical companies 

and the US government. 

Has received grant support from Amylin and Lilly. Serves as a consultant for 

Amylin, Lilly, and Takeda. Serves on the speaker bureau for Novo Nordisk. 

ROSALIND M. PETERS, PHD, RN 1 - P 35 


Wayne State University 

College of Nursing 

5557 Cass Avenue, 358 Cohn 


Dr. Rosalind Peters is a faculty member at Wayne State 

University College of Nursing. Her research focuses on discrimination 

as an etiologic factor in hypertension disparities as well as 

studying the self-care behaviors needed for hypertension control. 

She has received NIH funding to examine hypertension prevention 

beliefs of African Americans, as well as regional funding to 

examine the effects of psychosocial stressors on hypertension 

outcomes in African Americans. 

ILEANA L. PIÑA, MD - P 28 


Louis Stroke Medical Center - Cleveland 

Case Western Reserve University 

10701 East Boulevard, Dept of Cardiology -111 B (W) 

Cleveland, Ohio 44106-5038 

Dr. Ileana Piña, a Veterans Affairs National Quality Scholar, 

has served as director of: the Exercise Laboratory of the University 

of Miami; Heart Failure and Cardiac Rehabilitation at Hahnemann 

University; Cardiomyopathy at Temple University; and 

Heart Failure/Transplantation at Case Western Reserve University. 

Dr. Piña was the principal investigator in multiple heart failure 

trials including PRECISE (carvedilol), ELITE (losartan), ATLAS 

(lisinopril), CHARM(candesartan) and SCDHeFT. She served as 

chair of the steering committee of the NHLBI’s HF ACTION trial 

and as co-investigator in trials such as Bosentan, VEST. Dr. Piña 

is also a consultant for the Device section of the FDA. Dr. Piña 

has authored numerous publications in the area of heart failure, 

exercise and sex differences and collaborated to establish the 

HFSA Heart Failure Guidelines. She has edited the book Exercise 

and Heart Failure and The Year in Heart Failure 2004. 

Has received grant/research support from NIH-PI of Sub-Study for the HF- 

ACTION TRIAL. Serves as a consultant for FDA- Performs consultant duties for the 

FDA. Serves on the speaker bureau for AZ, Innovia, Merck, Sanofi-Aventis, Solvay, 

Novartis - presents, serves on panels as requested. 

OTELIO S. RANDALL, MD - P 18 


General Clinical Research Center 

Howard University Hospital 

520 N. Street, SW, S-617 

Washington, DC 20024 

Otelio S. Randall, MD, serves as professor, Department of 

Medicine/Division of Cardiovascular Diseases, Howard University 

Hospital, Howard University, Washington, DC. He obtained his medical 

degree from the University of Michigan in 1967 and completed a 

residency in medicine and a fellowship in cardiology there, before 

joining their faculty. Dr. Randall served as director, Coronary Intensive 

Care Unit, University of Michigan from 1974 until 1983. Dr. Randall 

is well-represented in clinical research endeavors/literature, with many 

original and collaborative works. He is sought after as an expert lecturer, 

specializing in the physiology and pathophysiology of hypertension, 

hypertension in the elderly, heart failure, arterial compliance, and 

preventive cardiology. 

Serves as a consultant for Boehringer Ingelheim, Novartis, Pfizer. Serves on 

the speaker bureau for Boehringer Ingelheim, Novartis, Pfizer. 


1 




JAMES W. REED, MD - P 23 

Professor of Medicine & Chief of Endocrinology 

Associate Chair, Clinical Medicine 


720 Westview Drive, SW 

Atlanta, Georgia 30310-1495 

Dr. James Reed, professor of medicine at Morehouse School 

of Medicine, has served as fellowship director for the Endocrine 

Fellowship at The Madigan Army Medical Center. He has implemented 

residency programs at The Eisenhower Army Medical 

Center and the Morehouse School of Medicine. He has served 

as chief of medicine at Eisenhower Army Medical Center and 

chairman of medicine at Morehouse School of Medicine. He is 

a past-president of the <strong>International</strong> <strong>Society</strong> on Hypertension in 

Blacks (6 years). He participates on numerous international and 

domestic advisory and policy-making bodies including the National 

Diabetes Advisory Board/NIDDK/NIH and the High Blood 

Pressure Coordinating Committee/NHLBI/NIH, JNC V, JNCVI 

and JNC VII. He is a retired Colonel from the US Army and holds 

the medals of Legion of Merit and Meritorious Service. 

Serves on the speaker bureau for Forest Laboratories. 

CARLOS JOSE RODRIGUEZ, MD, MPH 1 - P 18 

Assistant Professor 

Clinical Medicine and Clinical Epidemiology 

College of Physicians and Surgeons Columbia University 

Mailman School of Public Health 

Division of Cardiology 

622 W 168th Street, PH 3-342 

New York, New York 10032 

Dr. Carlos Rodriquez currently holds a joint appointment 

at Columbia University’s Mailman School of Public Health 

as assistant professor of Clinical Medicine and Clinical 

Epidemiology. He is the first Dominican from the Manhattan 

community of Washington Heights to be a full-time faculty in the 

Division of Cardiology at Columbia University Medical Center. 

Dr. Rodriquez’ areas of research interest include 

cardiovascular epidemiology, minority cardiovascular health, 

hypertensive heart disease, and stroke. His research has 

been published in a variety of journals including the Journal 

of the American College of Cardiology, American Journal of 

Cardiology, Hypertension, and Stroke. Dr. Rodriguez has been 

the recipient of the American Heart Association Clinically Applied 

Research Grant and the Association of Black Cardiologists 

Hawthorne - Searle Young Investigator Award. Dr. Rodriguez 

is currently the principal investigator of a Career Development 

Award funded by the National Heart Lung and Blood Institute. 

He is a Robert Wood Johnson Foundation Scholar and recipient 

of the Harold Amos Medical Faculty Development Award. 

ELIJAH SAUNDERS, MD - P 17, 22 


University of Maryland 


419 W. Redwood Street, Suite 620 

Baltimore, Maryland 21201 

Dr. Elijah Saunders is a professor of medicine, and head, 

Section of Hypertension in the Division of Cardiology at the 

University of Maryland School of Medicine, Baltimore, Maryland. 

He also serves as clinical associate professor of medicine at 

Meharry Medical College in Nashville, Tennessee, and is vice 

president for Graduate Medical Education and Affiliations at the 

University of Maryland Hospital. 

Dr. Saunders is a co-founder, past president and past 

chairman of the board of the <strong>International</strong> <strong>Society</strong> on 

Hypertension in Blacks (ISHIB). A fellow of the American College 

of Cardiology, American College of Physicians, American Heart 

Association Council on High Blood Pressure Research and the 

American College of Angiology and a certified specialist in 

Clinical Hypertension (American <strong>Society</strong> of Hypertension), Dr. 

Saunders has lectured extensively on hypertension, especially 

as it affects special populations, throughout the country and 

internationally. 

He is co-author of the medical textbook, Hypertension in 

Blacks: Epidemiology, Pathophysiology and Treatment, and a 

book for the public, High Blood Pressure. He is chief editor of 

the textbook, Cardiovascular Diseases in Blacks and is co-author 

of the Handbook of Management of Hypertension in African 

Americans. 

Has received research support from Abbott Laboratories, King Pharmaceuticals, 

Novartis, Pfizer, and Wyeth. Serves as a consultant for Abbott Laboratories, 

King Pharmaceuticals, Novartis, Pfizer, and Wyeth. Serves on the speaker bureau for 

Abbott Laboratories, King Pharmaceuticals, Novartis, Pfizer, and Wyeth. 

REAR ADMIRAL PENELOPE SLADE-SAWYER, PT, MSW 1 - P 17 

Director of the Office of Disease Prevention and Health Promotion 

United States Department of Health & Human Services 

200 Independence Avenue, SW, Rm 738-H 

Washington, DC 20201 

RADM Penelope Slade-Sawyer, PT, MSW, deputy assistant 

secretary for Health, Disease Prevention and Health Promotion, 

directs the Office of Disease Prevention and Health Promotion, 

Office of Public Health and Science in the US Department of 

Health and Human Services (HHS) and is the acting executive 

director of the President’s Council on Physical Fitness and Sports. 

RADM Slade-Sawyer is a commissioned corps officer in the US 

Public Health Service. RADM Slade-Sawyer is responsible for 

strengthening the disease prevention and health promotion priorities 

within the collaborative framework of the HHS agencies. 

She is a senior health advisor to the assistant secretary for Health 

and to the secretary of HHS. 

45 

45 

45 

DOMENIC A. SICA, MD 2 - P 13 

Professor of Medicine and Pharmacology Clinical Pharmacology & 


Virginia Commonwealth University 

Medical College of Virginia 

1101 East Marshall Street, Sanger Hall, Rm. 8062 P.O. Box 980160 

Richmond, Virginia 23298-0160 


1 


46 

46 

46 

JAMES R. SOWERS, MD - P 21 

Comprehensive Diabetes Center 

The University of Arizona College of Medicine 

4001 North Third Street 

Phoenix, Arizona 85012 

James R. Sowers, MD, is professor of medicine, Physiology/ 

Pharmacology, vice-chair for Research in the Department of 

Internal Medicine, and director of the Endocrinology, Diabetes 

& Metabolism Division at the University of Missouri School of 

Medicine. In addition, he is the director of the Thomas and Joan 

Burns Cardiovascular and Diabetes Research Center and holds the 

Thomas W. and Joan F. Burns Missouri Chair in Diabetology. He 

serves on the editorial boards of Hypertension, Endocrinology and 

the Journal of Hypertension, and is chief editor of the Journal of 

Cardiometabolic Syndrome. Dr. Sowers also serves as a reviewer 

on several study sections for the NIH and VA and is a member of 

the Safety and Monitoring Committee for the NIH ACCORD study. 

Dr. Sowers has conducted research on the cellular mechanisms 

of insulin action for three decades, focusing primarily on in vitro 

analysis of animal models. He has developed an international 

reputation in this field and routinely uses the methods to determine 

insulin action and oxidative stress in tissue. He serves as a coinvestigator 

on grants at the University of Missouri as well as other 

academic institutions. His ongoing scientific work has been funded 

by NIH and the Department of Veterans’ Affairs. 

Has received grant/research support from NIH, Novartis Pharmaceuticals, 

Veterans Administration. Serves as a consultant for Forest Laboratories and Novartis 

Pharmaceuticals. 

ANNE E. SUMNER, MD 1 - P 23 

Clinical Investigator Diabetes Branch 

National Institutes of Health 

4821 Montgomery Lane, Suite 105 

Bethesda, Maryland 20814 

Dr. Anne Sumner, an NIH tenure track investigator, focuses 

her research on understanding insulin resistance and fat metabolism 

in Blacks. Her goal is to refine the metabolic syndrome paradigm 

in order to achieve the most effective profile to predict and 

prevent cardiovascular disease and diabetes in people of African 

ancestry. For her work, Dr. Sumner, a fellow of the American Heart 

Association and the American College of Physicians, has received 

outstanding researcher awards from both the Association of Black 

Cardiologists and the <strong>International</strong> <strong>Society</strong> on Hypertension in 

Blacks. In addition, Dr. Sumner was recently elected to the Board 

of Governors of the Association of Black Cardiologists. 

SHELIA L. THORNE 2 - P 19 

President and CEO 

Multicultural Healthcare Marketing Group, LLC (MHMG) 

41 Brownstone Way, Suite 418 

Englewood, New Jersey 07631 

Ms. Thorne is president and CEO of the Multicultural 

Healthcare Marketing Group, LLC in Englewood, NJ. She is also 

an associate clinical professor at Stony Brook University School 

of Health Sciences. Ms. Thorne has spent almost three decades 

designing and implementing health promotional campaigns targeting 

communities of color and the healthcare professionals who 

treat them. She has facilitated numerous forums on health policy 

for local, state and federal health agencies. She has worked on 

behalf of the pharmaceutical, biotech and medical device industries 

throughout the United States, Western Europe and Latin America. 

J. KEVIN TUCKER, MD 2 - P 33 

Program Director and Assistant Professor of Medicine BWH/MGH 

Joint Nephrology Fellowship Program 

Harvard Medical School 

75 Francis Street 

Boston, Massachusetts 02115 

Dr. J. Kevin Tucker is a physician at Brigham and Women’s 

Hospital and assistant professor of medicine at Harvard Medical 

School. He is the director of the Joint Nephrology Training 

Program of Brigham and Women’s Hospital and Massachusetts 

General Hospital. Dr. Tucker’s clinical area of interest is in the 

care of patients on hemodialysis and peritoneal dialysis. 

DIANE E. WALLIS, MD 1 - P 34 

Midwest Heart Foundation 

1919 Highland Avenue, Bldg B, Suite 201 

Lombard, Illinois 60148 

Dr. Diane Wallis is a cardiologist with Midwest Heart Specialists 

and a clinical associate professor of medicine at Loyola 

University Stritch School of Medicine. Dr. Wallis is a graduate of 

Northwestern University Medical School in Chicago, with residency 

training and fellowship at Loyola University Medical Center 

in Maywood, Illinois. 

JAMES WILSON, MD 2 - P 27 

GV Montgomery Veteran’s Affairs Medical Center 

1500 E. Woodrow Wilson Drive 

Jackson, Mississippi 39216 

Dr. Wilson is professor of medicine at the University of Mississippi 

Medical Center in Jackson, and is a co-investigator of 

the Jackson Heart Study. He was born in Mississippi and received 

his medical degree from the University of Mississippi, with subsequent 

training in Internal Medicine and Rheumatology at Duke 

University and Brigham and Women’s Hospital in Boston. His 

primary research interests are in the genetics of cardiovascular 

disease and its risk factors. 

JACKSON T. WRIGHT, JR., MD, PHD - P 13 


Program Director 

William T Dahms Clinical Research Unit 

Director, Clinical Hypertension Program 

Case Western Reserve University 

11100 Euclid Avenue, Bolwell Suite 5098 

Cleveland, Ohio 44106 

Dr. Jackson Wright, Jr. is a professor of medicine, program 

director for the William T Dahms Clinical Research Unit, and 

director for the Clinical Hypertension Program at Case Western 

Reserve University. He has published extensively and has served 

on many national and international advisory panels. He cochaired 

the treatment section of JNC-7 and is a member of the 

JNC-8 committee. He has had a leadership role in nearly all of 

the major clinical outcome trials in Black populations during the 

past two decades. 

Has received grant/research support from AstraZeneca, GlaxoSmithKline, 

King Pharmaceuticals Company, Novartis, and Pfizer. Serves as a consultant for 

AstraZeneca, Bayer, Bristol Myers Squibb, Encysive, GlaxoSmithKline, King Pharmaceuticals 

Company, Merck & Co., Novartis, and Pfizer. 


1 



PartFour 

Abstracts

001 

DIABETES & STROKE HOSPITALIZED PATIENTS IN 2006: AN ANALYSIS OF HEALTHCARE COST BY RACE 

AND GENDER 

BA HUSAINI 1 ; V Cain 1 ; Z Samad; KB Merchant 1 ; RS Levine 2 ; M Moonis 3 

1 

Tennessee State University, 2 Meharry Medical College, 3 University of Massachusetts 

48 

48 

48 

Objective. Examine racial and gender differences in healthcare cost of Tennessee stroke patients with or without diabetes in 

2006. 

Background. Previous studies have examined the role of diabetes mellitus (DM) in the onset of stroke and its subsequent 

management. Impact of diabetes on healthcare cost of stroke patients remains unknown. We, therefore, examined three issues: (1) 

Do diabetic patients have a higher rate of stroke? (2) What is the effect of diabetes on stroke inpatient and total healthcare cost & 

does the cost vary by race & gender? (3) Do cost trends found in 2004 remain the same in 2006? 

Methods. Data of Tennessee stroke patients (N = 18,847; aged 35+) were extracted pertaining to stroke (ICD-9 codes 430- 

438), diabetes (type 1 + 2), race, gender, hospital days, stroke-related treatment cost, and total healthcare cost. The stroke sample 

included 55% females and 83% whites. DM was higher among stroke patients (32.2%) than non-stroke patients (24.9%; P



003 

EFFICACY OF THE VASODILATING, SELECTIVE β-BLOCKER NEBIVOLOL AS AN ADD-ON TO OTHER 

ANTIHYPERTENSIVES IN OBESE PATIENTS 

K FERDINAND 

Objectives. Obesity is a major risk factor for hypertension, which is difficult to control in obese patients, often requiring 

combination therapy. The current analysis evaluated the efficacy of nebivolol, a cardioselective β1-blocker with nitric-oxide– 

mediated vasodilating effects, added to other antihypertensives in obese (body mass index [BMI] ≥30) hypertensive patients. 

Methods. Adults with stage I-II hypertension (mean sitting office diastolic BP [SiDBP] ≥90 mm Hg and ≤109 mm Hg) 

receiving a stable antihypertensive treatment regimen consisting of ≥1 but ≤2 of an angiotensin-converting enzyme inhibitor, 

angiotensin II receptor blocker, or diuretic were randomized to once-daily nebivolol (5, 10, or 20 mg) or placebo in a 12-week, 

double-blind, multicenter trial. Patients with BMI >35 were excluded. Efficacy endpoints included the baseline-adjusted mean 

change in trough SiDBP (primary) and sitting systolic BP (SiSBP; secondary). 

Results. 669 patients comprised the intent-to-treat population, of whom 197 (29.4%) were Black, and 351 (52%) were 

obese. Treatment groups were matched for age, gender, race, diabetes status, BMI, and use of antihypertensive medications. In the 

obese subgroup, baseline mean SiSBP/SiDBP was 146.2/96.5 mm Hg. At Week 12, mean change from baseline was 

–1.1±11.9/–3.2±8.8 mm Hg for placebo (n=81) vs –8.7±13.5/–6.4±8.3, –6.6±15.5/–7.5±8.8, and –8.5±15.3/–8.9±8.2 mm Hg for 

nebivolol 5 mg (n=92), 10 mg (n=89), and 20 mg (n=89), respectively (P

005 

ETHNIC DIFFERENCES IN RESPONSE TO INITIAL TREATMENT WITH VALSARTAN MONOTHERAPY OR 

COMBINATION VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ) IN PATIENTS WITH STAGE 2 HYPERTENSION 

JM FLACK 1 ; D Levy 2 ; A Rudolph 2 

1 

Wayne State University School of Medicine and the Detroit Medical Center, Detroit MI; 2 Novartis Pharmaceuticals Corporation, 

East Hanover NJ 

50 

50 

50 

Only 36.3% of African Americans (AA) achieve blood pressure control despite high levels of awareness. Previously, The 

Valsartan-Managing blood pressure Aggressively and evaluating Reductions in hsCRP (Val-MARC) trial comparing valsartan (V) 

to valsartan + hydrochlorothiazide (V/HCTZ) as initial therapy for stage 2 hypertension patients reported rapid and significantly 

greater BP reductions in patients receiving V/HCTZ vs V. A total of 1668 patients were randomized to V160 mg (n=836; AA=190) 

or V/HCTZ 160/12.5 mg (n=832; AA = 202) with force-titration to V 320 mg or V/HCTZ 320/12.5 mg at Week 2 and optional 

addition of HCTZ 12.5 mg at Week 6. In this post-hoc analysis, the effect of race on treatment response was evaluated. A total 

of 73% AA vs 57% Caucasian (C) with initial monotherapy received optional HCTZ, while 49% AA vs 39% C with initial V/ 

HCTZ received additional HCTZ. Four subgroups were analyzed: Initial V 160 → 320 mg (n=242;AA = 28); Mono up-titrated V 

320/12.5 mg (n=377; AA=101); Initial V/HCTZ 160/12.5mg → 320/12.5 mg (n=360; AA=64); and Combo-up-titrated V 320/25 

mg (n=256; AA= 73). The mean change from baseline in systolic BP at Week 2, 6 and 12 are shown below. BP lowering was similar 

in AA and C on monotherapy at week 6. However, in AA on initial V/HCTZ, similar BP lowering as with C was observed at week 

12 after optional addition of HCTZ. High-dose combination therapy was required to achieve similar BP response in AA and C in 

difficult to treat patients. 

Change in mean SBP from baseline (mm Hg) 

[95%CI] 

African Americans (AA) 

Initial V 160 → 320 mg -16.3 

[-22.9, -9.7] 

Mono up-titrated (optional HCTZ12.5mg) -7.5 

[-10.4, -4.5] 

Initial V/HCTZ 160/12.5mg → 320/12.5 mg -26.6 

[-30.4, -22.9] 

Combo-up-titrated (optional HCTZ) -15.2 

[-18.9, -12.0] 

Caucasians (C) 

Wk 2 Wk 6* Wk 12 Wk 2 Wk 6* Wk 12 

-33.8 

[-40.0, -27.7] 

-7.2 

[-9.9, -4.4] 

-33.9 

[-37.0, -30.7] 

-11.2 

[-14.6, -7.8] 

-23.6 

[-30.3, -16.9] 

-20.4 

[-23,9, -17.0] 

-29.6 

[-33.6, -25.5] 

-23.8 

[-27.7, -19.8] 

-22.1 

[-24.1, -19.9] 

-12.3 

[-14.0, -10.5] 

-26.4 

[-28.4, -24.3] 

-17.1 

[-19.4, -14.7] 

-32.9 

[-34.8, -30.9] 

-12.3 

[-14.0, -10.7] 

-37.5 

[-39.3, -35.6] 

-15.6 

[-17.9, -13.4] 

-27.1 

[ -29.5, -24.7] 

-23.1 

[-25.0, -21.2] 

-32.6 

[-34.7, -30.6] 

-24.8 

[-27.3, -22.1] 

* optional titration received at Wk 6 if SBP/DBP ≥ 140/90 mm Hg; 6% AA and 10% C with initial V and 9.6% AA and 10% C with initial V/HCTZ did not 

receive optional HCTZ, despite uncontrolled BP 

FacultyAbstractsExhibitorsSupporters



006 

INHIBITION OF HIV1 REPLICATION AND RESTORATION OF GLUCOSE, LIPIDS, HEMOGLOBIN LEVELS AND 

NITRIC OXIDE (NO) IMBALANCE IN HIV1 PATIENTS FROM GABON 

G Maka; J Loundou; PV MAVOUNGOU; MY Akoume Ndong; B Ongali; E Mavoungou; D Mavoungou 

Centre de Recherche sur les Pathologies Hormonales (CRPH), Université des Sciences de la Santé, Libreville, Gabon 

Background. Deregulations of blood levels in glucose, lipids, hemoglobin and nitric oxide (NO) are driven by HIV 

and HAART treatments. Dehydroepiandrosterone (DHEA), which has less effects on HIV1, prevent insulin resistance by down 

regulating adipocytes peroxisome proliferators activator gamma (PPARγ) receptors, inhibits also the interleukins 1,6,10 TNFα; 

thereby stimulating nitric oxide (NO). 

Herein, we test whether IM28, the potent analog of DHEA, can restore glucose and lipids induced by HIV and HAART 

in addition to its potency to inhibit HIV1. The study was undertaken on a cohort of 201 volunteer Gabonese HIV1 patients among 

which 90 carried opportunistic pathologies such as diabetes, hypertension, tuberculosis, malaria, skin rash, digestive rash and urinal 

rash, facial paralysis, language troubles, memory deficit, anorexia and anxiety. 

Methods. Patients received 50 mg/day/70kg of IM28 or DHEA and were monitored weekly by our physicians; their blood 

samples were analyzed accordingly. All protocols used were in compliance with the research and ethic guidelines of our institution 

and approved by the republic of Gabon. 

Results. No side effects attributable to IM28 were noticed regarding hepatic, cardiac and renal functions. No significant 

difference was seen with baseline of urea, creatinine, GOT and TGP. By contrast to patients treated with DHEA, normalization of 

glycemia, increased body weight, CD4 (P

007 

CHANGES IN GLUTATHIONE METABOLISM IN HYPERTENSIVE AFRICAN AMERICAN WOMEN 

H YANG; G Shan; LC Zhou; X Lin; ZM Guo 

Department of Cardiovascular Biology, Meharry Medical College, Nashville, TN 

52 

52 

52 

African Americans experience higher prevalence of cardiovascular diseases when compared to other populations. Reduction 

or elevation in glutathione has been shown to contribute to cardiovascular diseases. The objective of this study is to determine the 

levels of glutathione and proteins related to glutathione metabolism in African Americans. Blood samples (n=329) obtained from 

hypertensive and normotensive African Americans were assigned to eight groups: young (23-49 year-old) and old (51-71 year-old) 

men and women with or without hypertension. The level of plasma glutathione was measured using a spectrophotometric assay, and 

the activity and protein level of enzymes related to glutathione metabolism in the plasma and red blood cells were measured using 

spectrophotometric assays and Western blot analysis. Our data demonstrated that the plasma levels of total, oxidized and reduced 

glutathione in old hypertensive women increased by 50%, 40% and 70% when compared with the age-matched normotensive 

women. In addition, the protein levels of γ-glutamylcysteine synthetase (γ-GCS) and glucose-6-phosphate dehydrogenase 

(G6PD) in the red blood cells obtained from old hypertensive women were approximately 100-fold higher than in those from old 

normotensive controls, while the activity and protein level of glutathione peroxidase and glutathione reductase in these two groups 

of subjects were comparable. No significant difference was observed in the levels of glutathione and enzymes studied among young 

women, young and old men and women with or without hypertension. These data suggest that elevation in γ-GCS and G6PD 

could be responsible for the increased plasma glutathione level in the aged hypertensive women. 

008 

HEALTH LITERACY AND LANGUAGE PREFERENCE IN HISPANICS WITH CHRONIC KIDNEY DISEASE 

CM LORA; L Ackerson; C Anderson; M Bruce; E Carmona; B Gerber; E Lustigova; A Narva; L Nessel; SE Rosas; A Sehgal; 

S Steigerwalt; J Vijil; AS Go; JP Lash 

The Chronic Renal Insufficiency (CRIC) Study Group 

The role of health literacy (HL) and language preference in Hispanics with chronic kidney disease (CKD) is not known. 

In a cross-sectional analysis, we assessed HL (using the Short Test of Functional Health Literacy) and language preference in 327 

Hispanic participants with mild to moderate CKD enrolled in the Hispanic Chronic Renal Insufficiency Cohort Study and studied 

the relationship between these variables and estimated glomerular filtration rate (eGFR) and control of hypertension, diabetes and 

dyslipidemia. 

Spanish language preference (SPL) was reported by 82% of participants. Almost 40% could not read in either language 

and among those that could read, 43% had inadequate or marginal HL. SPL was associated with older age, lower income, lower 

educational level, higher blood pressure (BP) and decreased use of renin angiotensin system inhibitors compared to English language 

preference. Lower HL and inability to read were associated with increased prevalence of diabetes, higher BP, and depression, as well 

as poorer self-reported health. By multivariable analysis, inability to read was independently associated with poor BP control (BP > 

130/80). HL or language preferences were not associated with eGFR and control of diabetes and dyslipidemia in adjusted analyses. 

Lower levels of HL and SPL were significantly associated with lower socioeconomic status and poorer BP control in 

Hispanics with CKD. In addition, lower HL was associated with increased depression and poorer self-reported health. The 

importance of HL and SPL as potential risk factors for adverse renal and cardiovascular outcomes in Hispanics with CKD is being 

examined prospectively. 




009 

BUILDING PARTNERSHIPS IN URBAN COMMUNITIES THROUGH FOCUS GROUPS 

DE JONES; B Weaver; W Johnson; E Saunders 

The purpose of this focus group meeting was to seek input from urban hypertensive/diabetic patients on the development 

of a behavior change counseling tool. 

Objectives. To establish content validity for the Counseling for Behavior Change-36 (CBC-36), a tool purposed to facilitate 

teaching and activate conversation between the provider and patient. To relate the input received from the focus group meeting for 

refinement of items on the CBC-36. 

Methods. Patients from the Baltimore Cardiovascular Partnership received an invitation, by mail, to participate in this focus 

group meeting. Prior to the session the major objective of the meeting was established, and questions for the session were developed. 

Activities included self administration of the preliminary tool. Assessment of wording, applicability, and appropriateness of the 

preliminary tool was priority. Participants were asked to comment on each item, in addition to rating the items on a 4-point Likert 

scale as, “very important,” “important,” “of little importance,” “unimportant.” 

Results. Participants, N=14, were all African American. Self administration of the tool took approximately 12-15 minutes. 

Revising the wording of items for clarity, eliminating suggested items, and expressed satisfaction by participants resulted. Saturation 

seemed apparent by the end of the session. 

Conclusions. When asked, “What do you like about the tool?” participants stated, “It was quick and easy,” “helps you 

dialogue with your doctor about questions or concerns you may have about your particular situation,” and “it has a common cause 

or purpose.” As a result of this partnership, culturally sensitive adjustments were made to the CBC-36. 

53 

53 

53 

010 

DELAYED DIAGNOSIS/MANAGEMENT OF PRIMARY ALDOSTERONISM — HELP FROM THE WEB: A SUPPORT 

GROUP FOR PATIENTS STRUGGLING WITH THIS COMMON CAUSE OF DIFFICULT-TO-CONTROL HIGH BLOOD 

PRESSURE. 

CE Grim; S Hall S; V Murphy; HM PEARSON and the 500+ members of hyperaldosteronism at Yahoogroups.com 

Primary aldosteronism (PA) is characterized by drug-resistant HTN (ACEs, ARBs and BB don’t work) and, in advanced 

cases, disabling hypokalemia (LoK). An online group organized in 2002 by a single patient has grown into a world-wide support 

group. Many have made the diagnosis(Dx) themselves by searching the web after frustration with their health care team’s failure 

to recognize the association of LoK and drug resistant HTN. The average patient had seen 5 different Drs before Dx and average 

duration of poorly Rxed HTN was 10 (range 1-40) years. Average BP decreased from 212 ± 28/124 ± 23 mm Hg before DX to 131 

± 15/83 ± 12 after Rx. (spironolactone 60 mg/day or eplerenone 120/d ). 

Based on an analysis of 28 with confirmed PA, Dx should be suspected by the complex of drug resistant HTN (93%), 

nocturia (75%), muscle cramps/fatigue (60%), and ER visits for a syndrome headaches, chest pains, muscle cramps, and anxiety 

with severe HTN and LoK (90%) 

Despite the fact that the DASH diet should be a powerful treatment for this human model of aldo/salt HTN, only 14% 

had this recommended. 

We invite all caring for difficult HTN to visit hyperaldosteronism at Yahoo Groups to read the 15,000+ e-mails and the 

“Conn’s Stories” as we are certain they will recognize this syndrome in some of their own patients and be spurred to test for PA in 

their own practices. 


011 

PREVALENCE OF HTN IN AN HIV CLINIC IN NIGERIA: AN EPIDEMIC WITHIN AN EPIDEMIC? 

EO Ofondu; RA Onwuegbuchulam; CN Osondu; R Nwogu; W Okoro; CE GRIM 

54 

54 

54 

Early in the HIV-AIDS epidemic it was rare to encounter a patient with high blood pressure (HBP). With the advent of 

successful pharmaceutical control of viremia in AIDs, cardiovascular disease (CVD) has emerged as a common cause of disability 

and death. The role of the rise in BP with HIV Rx in the genesis of CVD is not well understood nor has the effect of HIV meds on 

BP itself been well studied. The key role of HTN in disability and death in those of African descent makes it likely that HTN will 

play a deadly role in those under long term treatment for HIV. 

We estimated the frequency of HTN (≥140/and or ≥90) in 405 patients being treated for HIV in the Federal University 

Hospital in Owerri, Imo State, Nigeria. Overall 23% of the patients had high blood pressure. Average age was 38 yrs. In the general 

medicine clinic we found only 9% of those without HIV had HTN. Their average age was 34 years. 

HTN has emerged as a major component of the chronic disease complex that must be managed in the long term care of 

those with HIV in Africa. 

Training of HIV staff to mastery in the measurement and management of blood pressure and the provision of 

antihypterensive medications as part of the armamentarium should be undertaken to quickly intervene in this epidemic within an 

epidemic. 

012 

QUALITY IMPROVEMENT FOR BLOOD PRESSURE (BP) MEASUREMENT: EFFECT OF TRAINING ON TERMINAL 

DIGIT PREFERENCE IN AN URBAN INTERNAL MEDICINE CLINIC 

A DALMAR; A Caceres; CE Grim; CM Grim 

Background. Accurate BP measurement is the key to accurate BP diagnosis and treatment. A simple way to monitor 

the quality of BP in a clinic is to monitor terminal digit (TD) distribution (0,2,4,6,8) of recorded BPs. The most common TD 

is zero which leads to underestimation or overestimation of BP reading. The purpose of this study is to assess the accuracy of BP 

measurement using TD as an indicator in an urban clinic serving 4,000 patients a year (70% African American). 

Methods. We tested the effect of a standardized 6-hour training of clinic personnel using the Shared Care Method to 

validate mastery of knowledge for an accurate BP measurement. We assessed the effect of this training on TD bias by tabulating TD 

distribution the 3 months before and 3 months after the training. 

Results. There was a striking improvement in TD bias. The result also showed a higher mean SBP after training, but the 

percentage of persons with high blood pressure were higher in the before group; that means there could be an overestimation of high 

blood pressure rate in this group. 

Conclusions. Inaccuracies in BP measurement in primary care clinic can be seen by terminal digit Bias analysis. TD biases 

analysis can be used as a quality indicator. Measurement can be improved through training. 




013 

EFFICACY OF AN AMLODIPINE/OLMESARTAN MEDOXOMIL (AML/OM)-BASED TITRATION REGIMEN IN OBESE 

OR NON-OBESE PATIENTS WITH HYPERTENSION 

H PUNZI 1 ; A Shojaee 2 ; J-F Maa 2 ; N Patel 2 

1 

Trinity Hypertension Research Institute/Texas Woman’s University, USA; 2 Daiichi Sankyo, Inc., USA 

A post hoc analysis of a 12-week, titrate-to-goal study in obese/non-obese patients (BMI ≥30 or

014 

EFFICACY OF OLMESARTAN MEDOXOMIL (OM) AND HYDROCHLOROTHIAZIDE (HCTZ) IN ELDERLY (65 

YEARS) PATIENTS WITH HYPERTENSION: A POST HOC ANALYSIS OF PATIENTS WITH ISOLATED SYSTOLIC 

HYPERTENSION 

DJ KEREIAKES 1 ; J-F Maa 2 ; R Dubiel 2 ; A Shojaee 2 

1 

The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ 

Hospital, Cincinnati, OH, USA; 2 Daiichi Sankyo, Inc, Parsippany, NJ, USA 

56 

56 

56 

The effect of OM±HCTZ on BP in 178 elderly patients with hypertension was evaluated by 24-hour ambulatory BP 

monitoring (ABPM) and seated cuff BP (SeBP) in an open-label, dose titration study. Following placebo run-in (2-3 weeks), 

patients started OM 20 mg, uptitrated at 3-week intervals to OM 40 mg, OM/HCTZ 40/12.5 mg then OM/HCTZ 40/25 mg. 

Patients were uptitrated if SeBP ≥120/70 mm Hg. If SeBP



015 

IMPACT OF RACE ON BP REDUCTION AND GOAL ACHIEVEMENT OF OLMESARTAN MEDOXOMIL-BASED 

TREATMENT IN PATIENTS WITH TYPE 2 DIABETES 

JM NEUTEL 1 ; A Lewin 2 ; J-F Maa 3 ; A Shojaee 3 ; R Dubiel 3 

1 

Orange County Research Center, Tustin, CA, USA; 2 National Research Institute, Los Angeles, CA, USA; 3 Daiichi Sankyo, Inc., 

Parsippany, NJ 

A prespecified race, ie, Black and non-Black, subgroup analysis of a 12-week, open-label, single-arm, dose-titration study 

assessing efficacy and safety of olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) was performed in patients with 

type 2 diabetes and hypertension. Primary endpoint was the change from baseline (∆baseline) in mean 24-hr SBP as assessed by 

ambulatory BP monitoring (ABPM). Secondary endpoints included ∆baseline in mean 24-hr ambulatory DBP and in mean seated 

(Se) cuff BP; and proportion of patients achieving BP

016 

THE COMBINATION OF AMLODIPINE + OLMESARTAN MEDOXOMIL PROVIDES NUMERICALLY GREATER 

REDUCTIONS IN BLOOD PRESSURE COMPARED WITH COMPONENT MONOTHERAPIES IN RACE AND ETHNIC 

SUBGROUPS 

S OPARIL 1 ; D Ramstad 2 ; M Melino 3 ; J Lee3; R Heyrman 3 

1 

University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA; 2 Lakeview Medical Center, Suffolk, VA, USA; 

3 

Daiichi Sankyo, Inc., Parsippany, NJ, USA 

58 

58 

58 

Racial/ethnic differences in the blood pressure (BP) lowering efficacy of amlodipine (AML) + olmesartan medoxomil (OM) 

combination therapy vs respective monotherapy components were investigated. A randomized, double-blind, placebo-controlled, 

8-week factorial-design study was conducted in patients with hypertension (SeDBP 95-120 mm Hg) to determine if AML 5-10 mg/ 

day + OM 10-40 mg/day had significant efficacy benefits vs monotherapy. The primary endpoint was change from baseline in mean 

SeDBP at end of study (LOCF). Secondary endpoints included change from baseline in mean SeSBP and proportions of patients 

reaching BP goal (



017 

EFFICACY OF AN AMLODIPINE/OLMESARTAN MEDOXOMIL (AML/OM)-BASED TITRATION REGIMEN IN BLACK 

OR NON-BLACK PATIENTS WITH HYPERTENSION 

DJ KEREIAKES 1 ; JM Neutel 2 ; A Shojaee 3 ; WF Waverczak 3 ; R Dubiel 3 ; J-F Maa 3 

1 

Christ Hospital Heart and Vascular Center/The Lindner Research Center, USA; 2 Orange County Research Center, USA; 3 Daiichi 

Sankyo, Inc, USA 

A prespecified analysis of a 12-week, titrate-to-goal study in Black/non-Black patients with hypertension is presented. 

Following placebo run-in, patients were treated with AML 5 mg. If mean seated cuff (Se) BP was ≥120/80 mm Hg, patients were 

uptitrated at 3-week intervals to AML/OM 5/20 mg, AML/OM 5/40 mg and AML/OM 10/40 mg. The primary endpoint was 

change from baseline in mean 24hr SBP measured by ambulatory blood pressure monitoring (ABPM) at Week 12. Baseline/Week 

12 ABPM results were available for 172 patients. Baseline mean age (±SD) was 56.8±9.3 years with 105/185 (56.8%) male patients 

and 103/185 (55.7%) with Stage 2 hypertension. BP reductions from baseline in Black and non-Black subgroups were similar. 

AML/OM treatment was well-tolerated. 

59 

59 

59 

Mean 24-Hour ABPM 

Baseline BP BP Reduction BP

018 

EFFICACY OF AN AMLODIPINE/OLMESARTAN MEDOXOMIL (AML/OM)-BASED TITRATION REGIMEN IN 

PATIENTS WITH OR WITHOUT DIABETES AND HYPERTENSION 

H PUNZI 1 ; A Lewin 2 ; T Littlejohn III 3 ; A Shojaee 4 ; WF Waverczak 4 ; R Dubiel 4 ; J-F Maa 4 

1 

Trinity Hypertension Research Institute/Texas Woman’s University, USA; 2 National Research Institute, USA; 3 Piedmont Medical 

Research Associates, USA; 4 Daiichi Sankyo, Inc., USA 

60 

60 

60 

A prespecified analysis of a 12-week, titrate-to-goal study based on type 2 diabetes status in patients with hypertension is 

presented. Following placebo run-in, patients received AML 5 mg. If cuff BP ≥120/80 mm Hg, patients were uptitrated at 3-week 

intervals to AML/OM 5/20 mg, AML/OM 5/40 mg and AML/OM 10/40 mg. The primary endpoint was change from baseline in 

mean 24hr SBP measured by ambulatory blood pressure monitoring (ABPM) at Week 12. 

Baseline mean age (±SD) was 56.8±9.3 years. There were 105/185 (56.8%) male patients and 103/185 (55.7%) had Stage 

2 hypertension. Baseline/Week 12 ABPM results were available for 172 patients. Mean 24-hr ABPM targets of



019 

THE ASSOCIATION BETWEEN HEALTH LITERACY AND GLYCEMIC CONTROL AMONG MEXICAN AMERICAN 

DIABETICS WITH CHRONIC KIDNEY DISEASE: A PRELIMINARY REPORT FROM THE PASO DEL NORTE KIDNEY 

DISEASE STUDY (PNKDS) 

P Ragland; N Vega; A Fester; D Vasquez; T Alhamad; S Connery; F Madero; R Alfaro; J Dahu; F Payan; M Chauvet; P Tarwater; 

GT HERNANDEZ 

Objective. To evaluate the relationship between health literacy (HL) and glycemic control in Mexican American diabetics 

with chronic kidney disease (CKD). 

Methodology. Beginning in 6/2008, we have been recruiting patients with CKD stages 2-4 attending our renal clinic. 

Subjects had their HL measured with the short-form Test of Functional Health Literacy in Adults (s-TOFHLA). The s-TOFHLA 

scores are categorized as “inadequate HL” (0-16); “marginal HL” (17-22); and “adequate HL” (23-36). The outcome was poor 

glycemic control--a hemoglobin A1c (HbA1c) ≥ 7%. We used logistic regression to obtain the odds ratio (OR) of poor glycemic 

control comparing subjects with inadequate vs marginal/adequate HL and adjusted for gender, age, insurance, education, income, 

birthplace, language preference, hypertension and smoking. 

Results. 64 diabetic patients have enrolled. The mean age is 61.5 years; 47% are female; and 92% are Mexican American. 

34% of subjects had inadequate HL, 7% had marginal HL, and 59% had adequate HL. 59% of subjects had a HbA1c ≥ 7%. 

Subjects with inadequate HL were more likely to have poor glycemic control compared to those with marginal/adequate HL (OR, 

6.34; 95% confidence interval 0.78-51.3, P=.083). 

Conclusions. Among Mexican American diabetics with CKD, there is a strong association between inadequate HL and 

poor glycemic control. Our study is limited by the small number of patients recruited thus far, which may explain why statistical 

significance was not strictly met. Physicians should be aware of patients with inadequate HL, as they may be at risk for poor 

glycemic control and subsequent diabetic complications. 

61 

61 

61 

020 

NEBIVOLOL IN HIGH-RISK, OBESE AFRICAN AMERICANS WITH STAGE 1 HYPERTENSION: EFFECTS ON BLOOD 

PRESSURE, NITRIC OXIDE BIOAVAILABILITY, AND VASCULAR FUNCTION 

N MERCHANT 1 ; T Haque 2 ; CD Searles 1 ; A Pandian 1 ; I Bridges 2 ; ST Rahman 2 ; KC Ferdinand 1 ; BV Khan 1 

1 

Emory University, Department of Cardiology, Atlanta, GA, United States 

2 

Atlanta Vascular Research Foundation, Atlanta, GA, United States 

Despite available medical treatment, the incidence and complications of hypertension continue to be high, especially 

among African Americans. Nebivolol is a highly cardioselective beta 1 receptor blocker agent with vasodilatory effects mediated 

by nitric oxide. This study evaluated the effects of 8-week nebivolol treatment (5-10mg/day) on blood pressure, nitric oxide 

bioavailability, and vascular function changes in obese African Americans with recently diagnosed Stage 1 hypertension (n=43). The 

primary study outcomes were changes in systolic and diastolic blood pressure and efficacy in reaching normotensive blood pressure 

(systolic

021 

THE METABOLIC SYNDROME DOES NOT EFFECTIVELY IDENTIFY DIABETES RISK IN BLACK AFRICANS: RESULTS 

OF A PILOT COMPARISON OF BLACK AFRICANS AND AFRICAN AMERICANS 

M Luercio; M Ricks; F Thomas; OE Imoisili; BV Miller; NA Avila; AE SUMNER 

62 

62 

62 

Metabolic syndrome (MetSyn) should carry a 5-fold risk of diabetes. However, the ability of MetSyn to predict diabetes 

risk in Black Africans (BA) is unknown. We compared diabetes risk factors and MetSyn prevalence in Blacks born in Africa but 

living in the USA to Blacks born in the USA (ie African Americans [AA]). Twenty-four BA (67% male, age 36±7y (mean±SD), BMI 

27.2±3.7) were matched by sex, age and BMI to 24 AA. Participants had oral glucose tolerance tests (OGTT), abdominal CT scans, 

minimal model determination of insulin resistance (SI) and β-cell function measured by acute insulin response to glucose (AIRg). 

MetSyn prevalence was 8% in both BA and AA. However, the combined prevalence of pre-diabetes and diabetes was higher in BA 

than AA (50% vs 8%) with an odds ratio of 11 (95%CI: 2.1-57.5). Insulin resistance (SI) and waist circumference did not differ 

by ethnicity, but BA had higher 2h glucose, more VAT and lower AIRg (Table). We conclude that as the prevalence of MetSyn was 

similar in BA and AA, but BA had a higher risk of diabetes, the MetSyn does not identify diabetes risk in BA. The higher 2h 

glucose, greater VAT and lower β-cell function in BA suggest the increased diabetes risk in BA is not a Type 1 error. A reformulation 

of MetSyn risk factors or thresholds could lead to a greater ability of the MetSyn to identify BA at risk for diabetes. 

Table: Metabolic Characteristics 

Black Africans African Americans P-value* 

2h glucose (mg/dL) during OGTT 144+35 116+19



023 

RELATIONSHIP BETWEEN INFLAMMATION AND HYPERTENSION IN BLACKS 

RE WATSON; C Pereira-Hicks; KV Sarikonda; VP Kotaru; GD Fink 

College of Human Medicine, Michigan State University 

The relationship between inflammation and hypertension (HTN) is still unclear. Increased plasma levels of inflammatory 

cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are seen in persons with preHTN and HTN. 

HTN and related target organ damage is more severe in Blacks than Whites, but few studies have compared inflammation in Black 

and White hypertensives. 

Objectives. Compare serum IL-6 and TNF-α in hypertensive and normotensive whites and blacks. 

Methods. Blood from 46 subjects was used to determine serum IL-6 and TNF-α levels. 26 HTN (White n=14, Black 

n=12), 20 normotensives (White n=12, Black n=8). Serum IL-6 and TNF-α levels were measured by chemiluminescent ELISA kits. 

No subjects had frank inflammatory disease. 

Results. IL-6 and TNF-α levels were higher in HTN than normotensives (P=0.018 and P=.013). There was a trend toward 

TNF-α levels being higher in White than Black HTN (P=.08). IL-6 levels were also higher in White than Black HTN, but the 

difference was not significant (P=.18). Blacks and Whites had same blood pressures, ages, and weights. 

Conclusions. There were trends toward higher serum IL-6 and TNF-α levels in White vs Black HTN. Is inflammation the 

process of repair of vascular damage in HTN rather than a cause of it? Is decreased inflammation a cause of the increased severity of 

HTN and increased end-organ damage in HTN in Blacks? 

63 

63 

63 

024 

A COMPARATIVE STUDY OF PREVALENCE AND MANAGEMENT OF ARTERIAL HYPERTENSION IN THE FRENCH 

CARIBBEAN REGION AND MAINLAND FRANCE 

V ZIZKA; N Ozier-Lafontaine; J Inamo 

Cardiology Dept, Fort de France, Martinique, French West Indies and Clinic Epidemiology, Georges Pompidou European Hospital, 

Paris, France 

Background. Recent reports suggested an increased severity of hypertension in the Caribbean with a higher incidence of 

stroke and end-stage renal disease, compared to mainland France or to other European countries. No direct comparative study of the 

epidemiological aspects of hypertension between the Caribbean region and any European country has been performed yet. 

Aims. To measure the difference between the French Caribbean area population and mainland France in the prevalence, 

awareness, treatment and control of hypertension 

Methods. Cross-sectional analysis of two cohorts of workers surveyed in the Caribbean (6113 subjects) and in mainland 

France (29487 subjects). Hypertension was defined either as the use of anti-hypertensive medications, or as blood pressure > 140/90 

mm Hg at two separate visits. 

Results. Mean age was 39.4 ± 8.9 years in the Caribbean cohort and 38.8 ± 9.6 years in the Metropolitan one. Caribbean 

women have a higher prevalence of hypertension than French women (18.4 vs 9.6%, P

025 

FAITH-BASED DASH LIFESTYLE PROGRAM FOR HYPERTENSION CONTROL IN AFRICAN AMERICANS CHURCH 

COMMUNITIES- PROGRAM OVERVIEW 

S DODANI 1 ; D Sullivan 1 ; J Rankins 2 ; M Mayo 1; L Appel 3; A Ely 1 ; J Ard 4 

1 

University of Kansas, Medical Center, Kansas City, Kansas; 2 Florida State University, Tallahassee, Florida; 3 Johns Hopkins 

University, Baltimore, Maryland; 4 University of Alabama, Birmingham, Alabama 

64 

64 

64 

Hypertension (HTN) is a highly prevalent risk factor for cardiovascular diseases (CVDs), and disproportionately affects 

African Americans (AAs). Besides medications, lifestyle interventions are also effective in lowering blood pressure (BP), and the 

“Dietary Approach to Stop Hypertension” (DASH) diet has been shown to significantly reduce BP in AAs. The PREMIER study 

(DASH diet and recommended lifestyle intervention), showed lower BP response in AAs as compared to other groups. Despite 

extensive publicity, DASH has not been widely adopted by the public. Barriers to healthy eating in general, and DASH foods 

specifically, have been described and include income, education, attitudes about foods, health beliefs, and availability issues. This 

study builds on our previous research in the AA community and church partnership. Using community-based participatory research 

(CBPR) approaches, the objective of this project is to modify, test and deliver “PREMIER lifestyle intervention into a faith-based 

(FB), culturally appropriate DASH (FB-DASH). FB-DASH is developed in partnership with AA church pastors and church officials 

along with guidance from experts from both PREMIER and DASH programs. This intervention is delivered to the community 

by church-health ministers under the supervision of a research team trained and supported by experts with overarching guidance 

from church pastors. In this cluster randomized community trial of AA high-risk church participants, the primary goal is to reduce 

systolic BP by at least 4 mm Hg, reduce diastolic BP (secondary outcome) by at least 2 mm Hg, and reduce weight (secondary 

outcome) by at least 10 pounds from baseline in high-risk AA congregation. If successful, this intervention can be implemented in 

many other church settings with potentially tremendous impact on public health. We present here the newly FB-DASH program 

modified from the PREMIER trial. 

026 

THE IMPACT OF PATIENT EDUCATION AND PHYSICIAN EDUCATION ON BLOOD PRESSURE CONTROL 

E SAUNDERS 1 ; W Johnson 1 ; F Shaya 2 ; B Weaver 1 ; CD Mullins 2 ; D Howard 1 ; C Foster 1 ; X Yan 2 ; N Norman 2 

1 

Division of Hypertension, University of Maryland School of Medicine, Baltimore, MD; 2 Department of Pharmaceutical Health 

Services Research, University of Maryland School of Pharmacy, Baltimore, MD 

Study Purpose. To assess the impact of patient education and physician education on blood pressure control in hypertension 

patients. 

Methods. The study was composed of 349 hypertension patients, part of the patient body who are enrolled in the 

Baltimore Partnership Programs to Reduce CVD Disparities project. The study design is a 2 × 2 factorial trial: patients and their 

physicians were randomly assigned to either intervention or control group, where the intervention group received patient/physician 

education and control group did not. Blood pressures were measured at baseline and after one year, when the intervention of 

the first period was conducted. We used multiple regressions to assess the effects of interventions on blood pressure change, with 

outcome variable being absolute blood pressure reduction. The models were adjusted for sociodemographic variables. 

Results. The majority of study subjects were patients who are Black (90.2%), female (67.9%), and under 65 years of age 

(73.1%). Mean pre- and post blood pressures were 148/89 mm Hg and 139/83 mm Hg, respectively. When controlling for other 

variables, SBP reduction was more steep among patients who received intervention (P=.0009). Physician education at this point 

does not appear to promote blood pressure reduction (P=.26). 

Conclusions. In this patient sample, intervention at the patient level seems to be effective in blood pressure control. 




027 

THE IMPROVEMENT OF DIABETES CONTROL AND DISEASE PROCESS AWARENESS AS A RESULT OF FACE-TO- 

FACE VS MAIL INTERVENTION AMONG PATIENTS WITH DIABETES MELLITUS 

R Winston 3 ; E SAUNDERS 1 ; F Shaya 2 ; A Laird 3 ; Z Lu 3 ; F Larkins 3 ; CD Mullins 3 ; S Jolly 3 ; W Johnson 1 ; B Weaver 1 

1 

Division of Hypertension, University of Maryland School of Medicine, Baltimore, MD; 2 Department of Pharmaceutical Health Services 

Research, University of Maryland School of Pharmacy, Baltimore, MD; 3 Bon Secours Baltimore Health System, Baltimore, MD 

Study Purpose. The purpose of this study was: 1) To assess the impact of different educational methods on Hemoglobin A1c 

control in diabetic patients; 2) To determine which educational method was more effective for patient disease process awareness and 

management based on Diabetes Mellitus Knowledge Tool Test scores in diabetic patients. 

Methods. Adult patients with type 2 diabetes were recruited from community-based primary care physician offices. The 

study subjects were a subset of those enrolled in the Baltimore Partnership Program to Reduce CVD Disparities project based on 

a minimum of one year of follow-up. Intervention patients received education either by face-to-face meeting or mail. Multiple 

regression models were used to assess the effects of different educational methods on change of HbA1c and patients’ awareness and 

management of the disease process. 

Results. Most of the patients were African American (90.77%), females (66.26%), and the mean age was 64.33 years. The 

HbA1c reduction was larger in patients who received informal face-to-face education (-1.19%), as compared to the patients who 

received mail education (-0.72%). The scores increased from baseline were greater in patients who received informal face-to-face 

education (18.90%), as compared to patients who received only mail education (14.40%). Both were significant at alpha 0.05. 

Conclusions. There is a strong indication that increased knowledge and awareness coincide with the tighter HbA1c 

control. Patient educational programs based upon informal face-to-face interactions were more effective than programs where 

information is mailed to patients. 

65 

65 

65 


66 

66 

66 

Abstract Author Index 

Presenting author appears 

in capital letters 

Author Abstract Page 

Ackerson L #008 52 

AGYEMANG C #002 48 

Akoume Ndong MY #006 51 

Alfaro R #019 61 

Alhamad T #019 61 

Anderson C #008 52 

Appel L #025 64 

Ard J #025 64 

Avila NA #021 62 

Bhopal R #002 48 

Bridges I #020 61 

Bruce M #008 52 

Caceres A #012 54 

Cain V #001 48 

Carmona E #008 52 

Chauvet M #019 61 

Connery S #019 61 

Dahu J #019 61 

DALMAR A #012 54 

DODANI S #025 64 

Doumatey A #022 62 

Dubiel R #014 56 




Ely A #025 64 

FERDINAND K #003 49 

FERDINAND K #004 49 

Ferdinand KC #020 61 

Fester A #019 61 

Fink GD #023 63 

FLACK JM #005 50 

Foster C #026 64 

Gerber B #008 52 

Go AS #008 52 

Grim CE #012 54 

Grim CE #010 53 

GRIM CE #011 54 

Grim CM #012 54 

Guo ZM #007 52 

Hall S #010 53 

Haque T #020 61 

HERNANDEZ GT #019 61 

Heyrman R #016 58 

Howard D #026 64 

HUSAINI BA #001 48 

Imoisili OE #022 62 

Imoisili OE #021 62 

Inamo J #024 63 

Johnson W #009 53 



Jolly S #027 65 

JONES DE #009 53 

KEREIAKES DJ #017 59 

KEREIAKES DJ #014 56 

Khan BV #020 61 

Kotaru VP #023 63 

Kunst A #002 48 

Laird A #027 65 

Larkins F #027 65 

Lash JP #008 52 

Lee J #016 58 

Levine RS #001 48 

Levy D #005 50 

Lewin A #015 57 

Lewin A #018 60 

Lin X #007 52 

Littlejohn III T #018 60 

LORA CM #008 52 

Loundou J #006 51 

Lu Z #027 65 

Luercio M #021 62 

Lustigova E #008 52 

Maa J-F #014 56 

Maa J-F #013 55 

Maa J-F #017 59 

Maa J-F #018 60 

Maa J-F #015 57 

Madero F #019 61 

Maka G #006 51 

Mavoungou D #006 51 

Mavoungou E #006 51 

MAVOUNGOU PV #006 51 

Mayo M #025 64 

Melino M #016 58 

Merchant KB #001 48 

MERCHANT N #020 61 

Miller BV #021 62 

Moonis M #001 48 

Mullins CD #026 64 

Mullins CD #027 65 

Murphy V #010 53 

Narva A #008 52 

Nazroo J #002 48 

Nessel L #008 52 

Neutel JM #017 59 

NEUTEL JM #015 57 

Norman N #026 64 

Nwogu R #011 54 

Ofondu EO #011 54 

Okoro W #011 54 

Ongali B #006 51 

Onwuegbuchulam RA #011 54 

OPARIL S #016 58 

Osondu CN #011 54 

Ozier-Lafontaine N #024 63 

Pandian A #020 61 

Patel N #013 55 

Payan F #019 61 

PEARSON HM #010 53 

Pereira-Hicks C #023 63 

PUNZI H #018 60 

PUNZI H #013 55 

Rankins J #025 64 

Ragland P #019 61 

Rahman ST #020 61 

Ramstad D #016 58 

Ricks M #021 62 

Rosas SE #008 52 

Rotimi CN #022 62 

Rudolph A #005 50 

Samad Z #001 48 

Sarikonda KV #023 63 

Saunders E #009 53 

SAUNDERS E #026 64 

SAUNDERS E #027 65 

Searles CD #020 61 

Sehgal A #008 52 

Shan G #007 52 

Shaya F #026 64 

Shaya F #027 65 

Shojaee A #018 60 





Steigerwalt S #008 52 

Stronks K #002 48 

Sullivan D #025 64 

SUMNER AE #022 62 

SUMNER AE #021 62 

Tarwater P #019 61 

Thomas F #021 62 

Unwin N #002 48 

Vasquez D #019 61 

Vega N #019 61 

Vijil J #008 52 

WATSON RE #023 63 

Waverczak WF #017 59 

Waverczak WF #018 60 

Weaver B #009 53 



Winston R #027 65 

Yan X #026 64 

YANG H #007 52 

Zaninotto P #002 48 

ZIZKA V #024 63 

Zhou J #022 62 

Zhou LC #007 52 



PartFive 

ExhibitorsSupporters

68 

68 

68 

 

<strong>ISHIB2009</strong> 

Exhibit Hall 

Layout 

and 

Poster 



Exhibit Hall Hours 


1:00 PM – 2:30 PM 

4:00 PM – 4:30 PM 

5:30 PM – 6:30 PM 


10:00 AM –11:30 AM 

2:30 PM – 3:30 PM 

4:30 PM – 6:30 PM 


10:00 AM – 11:00 AM 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




CardioDynamics-The ICG Company 

Booth 2 

In minutes, BioZ ICG (Impedance Cardiography) technology 

provides noninvasive hemodynamic parameters, 

including cardiac output and fluid status, for patients with 

heart failure, dyspnea, and resistant hypertension. ICG is 

a Medicare-covered test used in over 5 million patient applications 

to assist physicians select and optimize cardiovascular 

medications including ACEs, BBs, and diuretics. 

Daiichi Sankyo 

Booths 3 and 4 

Please visit Daiichi Sankyo, Inc., marketer of AZOR 

(amlodipine and olmesartan medoxomil), Benicar® 

(olmesartan medoxomil), and Benicar HCT® (olmesartan 

medoxomil-hydrochlorothiazide). AZOR is copromoted 

with Forest Laboratories. 

69 

69 

69 

Forest Laboratories 

Booth 6 

Forest Laboratories, Inc. welcomes you to Chicago, Illinois! 

We invite you to visit our exhibit where our professional 

representatives will welcome the opportunity to 

discuss and answer any questions regarding our product 

Bystolic (nebivolol). Please visit our website 

at www.bystolic.com. 

ISHIB 

Booth 9 

Be sure to visit the ISHIB host booth. Learn more about the 

professional education and community outreach programs 

provided by ISHIB. If you have not already done so, you 

can renew your membership at the ISHIB booth. Also, 

corporations can sign up to participate as a member of 

the Corporate Partners Roundtable at our booth. Pick up 

a copy of Ethnicity and Disease, our peer-reviewed professional 

journal. 

ISHIB is a unique, nonprofit, professional, medical membership 

society, whose mission is to eliminate cardiovascular 

health disparities in ethnic minority populations. 

Our organizational scope includes diabetes, stroke, lipid 

disorders, renal disease, obesity, and related cardiovascular 

risk factors. 

157 Summit View Drive 

McDonough, Georgia 30253 USA 

404.880.0343 

www.ishib.org 


70 

70 

70 


Booth 5 

GlaxoSmithKline is a leading research-based pharmaceutical 

company with a powerful combination of skills to 

discover and deliver innovative medicines. We offer a number 

of programs to support effective health management 

strategies and improve patient care. Please visit our exhibit 

to learn more about our products. 

Three Franklin Plaza 

1600 Vine Street 

Philadelphia, PA 19101 

www.gsk.com 

800-366-8900 

Omron Healthcare 

Booth 8 

Omron Healthcare strives to develop products (BP Monitors; 

Wellness products) that provide accurate health information 

to consumers and physicians and that support positive lifestyle 

changes and health improvement. By enabling people 

to accurately monitor certain aspects of their day-to-day 

health at home, Omrom Healthcare is making it easier for 

people to work with their medical professionals to prevent 

and measure the progression of lifestyle diseases. 

1200 Lakeside Drive 

Bannockburn, IL 60015 

847.247.5637 

johnna.purcell@omron.com 

www.omronhealthcare.com 

Novartis Pharmaceuticals Corporation 

Booth 7 

Novartis Pharmaceuticals Corporation is dedicated to discovering, 

developing, manufacturing and marketing prescription 

drugs that help meet our customers’ medical needs and 

improve their quality of life. Please visit the Novartis exhibit 

where our professional sales representatives are available to 

answer questions and discuss our products. 

One Health Plaza 

East Hanover, N.J. 07936-1080 

www.novartis.com 

US Food & Drug Administration 

Booth 1 

The U.S. Food and Drug Administration Office of Women’s 

Health addresses the health issues of the nation’s women by 

funding scientific research, collaborating with national organizations 

to sponsor outreach efforts, and disseminating free 

publications on a variety of topics including hypertension, 

diabetes, medication safety, heart disease, and smoking 

cessation. 




2009 ISHIB Supporters 

Platinum 

71 

71 

71 

Diamond 

Gold 



& Risk Reduction in African American 

Patients With Metabolic Syndrome: 

What Are the Best Approaches? 

FRIDAY, JULY 

10 th 

6:30 PM–8:30 PM 

09 

RENAISSANCE CHICAGO HOTEL, 1 WEST WACKER DRIVE, CHICAGO IL Grand Ballroom I, II, III 

AGENDA 

Each presentation will include audience response. 

6:30 PM Welcome/Overview of Educational Objectives 

Keith C. Ferdinand, MD (Program Chair) 

6:40 PM Components of the Metabolic Syndrome in African American Patients 

James R. Sowers, MD, FACE, FACP, FAHA 

7:00 PM Inflammatory Markers in Cardiovascular Disease and Hypertension 


7:20 PM Combination Therapy in African Americans With Hypertension and 

Metabolic Syndrome: What Are the Best Choices? 


7:40 PM Faculty Panel Discussion 

Cases in Point: African American Patients With Hypertension and 

Metabolic Syndrome—Managing Clinical Challenges 

Moderated by Keith C. Ferdinand, MD 

8:30 PM Program Summary and Closing Remarks 


FACULTY 


Adjunct Clinical Professor, Morehouse 


Clinical Professor, Emory University 


Association of Black Cardiologists 

(ABC), Inc. 

Atlanta, Georgia 

James R. Sowers, MD, 

FACE, FACP, FAHA 

Thomas W and Joan F. Burns Missouri 

Chair in Diabetology 

Director of the MU Diabetes and 

Cardiovascular Center 

Professor of Medicine, Physiology 

and Pharmacology 

University of Missouri – Columbia 

Medicine Health Sciences Center 

Columbia, Missouri 


Associate Professor Internal 

Medicine – Hypertension 

University of Texas Southwestern 

Medical Center 

Medical Director, Parkland 

Hypertension Clinic 

Dallas, Texas 

EDUCATIONAL OBJECTIVES: 

Upon completion of this activity, participants should be better able to: 

List the components of the metabolic syndrome and how these components manifest uniquely in 

African American patients 

Outline how biomarkers are used to determine risk of cardiovascular disease 

Using a case-based model, define the utility of antihypertensive combinations to manage hypertension 

in African American patients with both hypertension and metabolic syndrome, and novel approaches 

used to assess vascular status 

TARGET AUDIENCE: Cardiologists and 

other healthcare professionals involved in the 

treatment of patients with hypertension. 

EDUCATIONAL METHOD: Lectures 

with slides, audience response, opportunity for 

Q&A, and a syllabus. 

CME INFORMATION 

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education 

(ACCME) through the joint sponsorship of the American <strong>Society</strong> of Hypertension, Inc. and ISHIB. The American <strong>Society</strong> of Hypertension, Inc. is accredited by the ACCME to provide continuing medical 

education for physicians. 

Designation Statement: The American <strong>Society</strong> of Hypertension, Inc. designates this educational activity for a maximum of 2.0 hours AMA PRA Category 1 credits. Each physician should claim 

credit commensurate with the extent of their participation in the activity. CE credits for nurses, dietitians, and other healthcare professionals requiring continuing education credits will be provided by 

ISHIB. ISHIB has been reviewed and approved as an authorized provider by the <strong>International</strong> Association for Continuing Education and Training (IACET) and uses the criteria and guidelines designated 

by that organization as the basis for granting continuing education units (CEUs). Participants who successfully complete this activity can receive up to .2 CEUs. CE credits for pharmacists will be 

provided by the National Pharmaceutical Association. 

Disclosure Statement: The American <strong>Society</strong> of Hypertension, Inc. strives to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All presenters in such 

activities are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the session in which they are participating. 

This pertains to relationships, in place at the time of the activity or in the twelve (12) months preceding the activity, with pharmaceutical companies, biomedical device manufacturers, or other 

corporations whose products or services are related to the subject matter of the presentation topic. Speakers are also expected to openly disclose any off-label, experimental, or investigational use of 

drugs or devices in their presentations. 

Jointly sponsored by the American <strong>Society</strong> of Hypertension, Inc. and the 

<strong>International</strong> <strong>Society</strong> on Hypertension in Blacks, Inc. 

This activity is supported by an educational grant 

from Daiichi Sankyo, Inc.

Glycemic Targets 

in Patients with 

Type 2 Diabetes: 

A NEW ERA? 

SATURDAY, JULY11 th 

11:30 AM–1:30 PM 

RENAISSANCE CHICAGO HOTEL, 

1 WEST WACKER DRIVE 

CHICAGO IL 


2009 

FACULTY 

Kwame Osei, MD, FACE, FACP 

Ralph W. Kurtz, Chair of Endocrinology 

Director, Division of Endocrinology, 

Diabetes & Metabolism 

Professor of Medicine and Exercise 

Physiology 

Ohio State University Medical Center 

Columbus, Ohio 


Adjunct Clinical Professor, Morehouse 


Clinical Professor, Emory University 


Association of Black Cardiologists (ABC), Inc. 


David M. Kendall, MD 

Medical Director and Chief – Clinical and 

Professional Services 

<strong>International</strong> Diabetes Center 


University of Minnesota 

Minneapolis, Minnesota 

AGENDA 


11:30 AM Welcome/Overview of Educational Objectives 

Kwame Osei, MD, FACE, FACP (Program Chair) 

11:40 AM Hypoglycemic Targets: Interpreting Latest Clinical 

Trial Evidence 

David M. Kendall, MD 

12:10 PM Managing CV Risk in African Americans With 

Type 2 Diabetes and Hypertension 


12:40 PM Faculty Panel Discussion: Managing Risk in the African 

American Patient With Hypertension and Diabetes: 

A New Era? 

Moderated by Kwame Osei, MD, FACE, FACP 


Kwame Osei, MD, FACE, FACP 

TARGET AUDIENCE: Cardiologists and other 

healthcare professionals involved in the treatment of 

patients with hypertension. 

EDUCATIONAL METHOD: Lectures with 

slides, audience response, opportunity for Q&A, and a 

syllabus. 



Recognize the issues related to hypoglycemic risk in patients with type 2 diabetes 

Cite current targets for effective management of type 2 diabetes and hypertension 

Apply an integrated approach to managing cardiovascular risk, including risk possibly 

associated with hypoglycemia, in patients with type 2 diabetes and hypertension 



(ACCME) through the joint sponsorship of the American <strong>Society</strong> of Hypertension, Inc. and ISHIB. The American <strong>Society</strong> of Hypertension, Inc. is accredited by the ACCME to provide continuing 

medical education for physicians. 














from Takeda Pharmaceuticals North America.

Saturday 

July 

11 th 

6:30 PM–8:30 PM 

Oxidative Stress, Endothelial Function 

and Beta Blockade in 

Hypertensive Disease: A Fresh 

Look at African American Patients 

RENAISSANCE CHICAGO HOTEL, 1 WEST WACKER DRIVE, CHICAGO IL Grand Ballroom I, II, III 

Faculty 

Kenneth A. Jamerson, MD 

Professor, Division of Cardiovascular 

Medicine 

University of Michigan Medical School 

Medical Director of the Program for 

Multicultural Health 

University of Michigan Health System, 

Ann Arbor, Michigan 

Gary H. Gibbons, MD 

Director, Cardiovascular Research Institute 

Chairman, Department of Physiology 




Elizabeth Ofili, MD, MPH, FACC 


Chief of Cardiology and Director of the 

Clinical Research Center 



Agenda 


6:30 PM Welcome/Overview of Educational Objectives 

Kenneth A. Jamerson, (Program Chair) 

6:45 PM Oxidative Stress, Endothelial Function, and Beta Blockade: 

Newest Findings 

Gary H. Gibbons, MD 

7:15 PM Hypertensive Disease Management in African Americans: 

Interpreting the Role of Beta Blockade 

Elizabeth Ofili, MD, MPH, FACC 

7:45 PM Questions From the Audience 

8:00 PM Faculty Case Discussion: An Elderly African American 

Patient With Hypertension and Angina 

Moderated by Kenneth A. Jamerson, MD 


Kenneth A. Jamerson, MD 



Describe the links between oxidative stress, endothelial function, and hypertensive disease progression 

List the latest findings describing the effect of beta blockade on mechanisms of hypertensive disease 

progression 

Address the preexisting myths surrounding use of beta blockade in African American patients using an 

evidence-based approach 

Using a case-based model, discuss the appropriate role for beta blockade in management of elderly 

African American patients with both hypertension and angina 

TARGET AUDIENCE: Cardiologists and 

other healthcare professionals involved in the treatment 

of patients with hypertension. 

EDUCATIONAL METHOD: Lectures 

with slides, audience response, opportunity for Q&A, 

and a syllabus. 



(ACCME) through the joint sponsorship of the American <strong>Society</strong> of Hypertension, Inc. and ISHIB. The American <strong>Society</strong> of Hypertension, Inc. is accredited by the ACCME to provide continuing 

medical education for physicians. 














from Forest Laboratories, Inc.



75 

75 

75 

Notes

2010 MEMBERSHIP RENEWAL/INVOICE APPLICATION 

10% DISCOUNT DEADLINE: March 31, 2010 

FEDERAL TAX ID: 58-1718541 

PLEASE COMPLETE INFORMATION 

NAME DEGREE 

TITLE 

COMPANY 

DEPARTMENT 

ADDRESS 

CITY STATE POSTAL CODE 

COUNTRY 

TELEPHONE 

FAX 

EMAIL 

ASSISTANT NAME 

ASSISTANT EMAIL 

MEMBERSHIP CATEGORY 

MEMBERSHIP IS FOR CALENDAR YEAR (JAN 1 – DEC 31, 2010). PAYMENT MUST ACCOMPANY APPLICATION 

Lifetime payment of $2,500 

10% discount off full payment $2,250 

LIFETIME MEMBERSHIP 

Lifetime – 3 installments of $834 

10% discount on installment $750.60 

(Year 1 Year 2 Year 3 ) 

ANNUAL MEMBERSHIP 

ONE YEAR (2010) TWO YEARS (2010/11) THREE YEARS (2010/11/12) 

Regular: (Practicing Healthcare Professional) 

$180 

10% discount $162 

$360 


$540 


Associate: (Non-Practicing Healthcare Professional) 

$150 

$300 



Student: (graduate/professional school), Residents/Fellows) 

$75 

$150 

10% discount $67.50 


$450 


$225 

10% discount $202.50 

METHOD OF PAYMENT 

NOTE: PAYMENT WILL BE PROCESSED IMMEDIATELY 

Enclosed is a Personal Check Institutional/Company check Money Order 

Please charge my Visa MC AMEX Discover 

Card Number 

Expiration Date MO YR 

NAME OF CARD HOLDER 

CARDHOLDER’S SIGNATURE 

NOTE: Cardholder’s Signature (Typed name will serve as signature for EMAIL VERSION ONLY) 

SEND COMPLETED APPLICATION 

EMAIL: Save this document and email to ishib@ishib.org 

FAX: Print and fax to 404.880.0347 

MAIL: Print and mail to: 

ISHIB 


McDonough, GA 30253 

FOR OFFICIAL USE ONLY DATE AN CHECK/MONEY ORDER . 

157 SUMMIT VIEW DRIVE • MCDONOUGH, GEORGIA 30253 USA • PHONE: 404.880.0343 • FAX: 404.880.0347 • WWW.ISHIB.ORG

ISHIB invites all healthcare professionals and students to submit abstracts, 

concerning the treatment and prevention of hypertension and related disorders, 

to be considered for presentation at the ISHIB2010 scientific meeting. Authors 

from past conferences have assisted in an exchange of information critical to 

the global understanding of hypertension and chronic disorders among ethnic 

minority populations. 

ISHIB2010 

Call for Papers 

Abstract Submittal 

Guidelines 

• 200-250 word count; tables and charts 

allowed, with reduced word count. 

Abstracts exceeding 250 words may be 

truncated. 

• Organize the abstract by 

1) brief description of objectives; 

2) statement of the methods used; 

3) summary of results; 

4) conclusions. 

• Define all abbreviations the first time 

they appear in the abstract. 

• Avoid formulas. 

• Use only the generic names of drugs. 

• Do not include references, credits, or 

mention of grant support. 

• Single space all typing; no space 

between title and body or between 

paragraphs. 

• Indent each paragraph with a tab. 

• Submit computer file of abstract. File 

must be in a PC-compatible format, 

preferably Microsoft Word. 

• Proofread the abstract carefully before 

submitting; abstracts will be published as 

submitted in the conference syllabus. 

Grading/Presentation 

Guidelines 

• Abstracts will be scored by the 

ISHIB2010 Abstract Review Committee 

according to scientific merit, relevance 

to health of ethnic minority populations, 

and expertise of presentation. 

• All accepted abstracts will be 

presented as posters at ISHIB2010. As 

determined by the review committee, 

exceptional work will be selected for 

moderated merit poster sessions or oral 

presentation. 

• A presenting author must attend the 

conference and present the abstract. 

Abstracts will not be considered without 

a completed conference registration 

from the presenting author. 

Contact Information/Cover 

Letter 

• Submit name of corresponding 

author. All correspondence, including 

acknowledgment of receipt, will be 

directed to the corresponding author. 

• Include the following information for the 

corresponding/lead author: Name (first, 

middle, last); Degree; Title; Institution; 

Street Address; City; State; Country; 

Postal Code; Telephone (voice, fax, 

country code if outside of USA); Email. 

• Cover letter should include key words 

describing the abstract; these will be 

used to guide selection of reviewers. 

• Include the following statement and 

your signature in your submittal letter: 

“The author affirms that the material 

submitted has not been previously 

published or presented at any 

national or international meeting; any 

experimentation has been conducted 

according to a protocol approved 

by the institutional committee on 

ethics or, if no such committee exists, 

that it conforms with the principles 

of the Declaration of Helsinki of 

the World Medical Association 

(Clinical Research.1966:14:193). 

The undersigned also certifies that 

all authors named in the abstract 

have agreed to its submission for 

presentation at ISHIB2010: The 25th 

Annual <strong>International</strong> Interdisciplinary 

Conference on Hypertension and 

Related Cardiovascular Risk Factors in 

Ethnic Populations.” 

• Curriculum vitae of principal author 

must be included. 

Submit Abstracts 

online at abstracts@ishib.org (preferred) or 

send hard copy and disk to: 

ISHIB2010 Abstract Review Committee 


McDonough, Georgia 30253 USA 

Deadline: March 1, 2010 

Abstracts 

Abstracts may represent completed work 

or results of work in progress. Previously 

published or presented abstracts will not 

be considered. Topics may be in any of the 

scientific disciplines related to hypertension 

and cardiovascular risk factors. Other 

potential topics – as they pertain to ethnic 

minority populations – may include: 

• Hypertension and related cardiovascular 

conditions 

• Epidemiology of CVD 

• Causes/risk factors for hypertension and 

atherosclerosis 

• Prevention and treatment of CVD 

• Molecular biology of CVD 

• Diabetes and kidney disease 

• Health education/promotion in CVD and 

diabetes 

• Social issues/access to health care in 

under-served populations 

• Endocrine and metabolic disorders 

• Kidney disease 

• Hematologic disorders 

• Infectious diseases 

• GI disorders 

• Cancer 

• Neurology and mental health 

• Neonatology and pediatrics 

• Clinical pharmacology 

• Social/community medicine 

• Behavioral science approaches to health 

care for under-served populations 

For more information: 

contact ISHIB at 

404.880.0343 (v), 

404.880.0347 (f), 

visit www.ishib.org, or 

email to abstracts@ishib.org.

Join ISHIB 

in 2010 

25th Annual 

<strong>International</strong> 

Interdisciplinary 

Conference 

Check our website, 

www.ishib.org, 

for details. 

on Hypertension 

and Related 

Cardiovascular 

Risk Factors 

in Ethnic Populations.

ISHIB2009 - International Society on Hypertension in Blacks

Create successful ePaper yourself

Delete template?

Save as template?